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Chapter 1




Electrostatic interactions play a vital role in the interplay of biomacromolecules, 
such as protein and nucleic acids. Electrostatic repulsion, on the other hand, prevents 
unfavorable interactions that might lead to uncontrolled aggregation. Most naturally 
occurring proteins are only moderately charged at physiological conditions. Natural 
proteins with uncommonly high net charges are often partially or completely disordered 
in solution, due to repulsion forces between uncompensated charges. Moreover, many 
highly charged, disordered proteins are resilient to heat inactivation. Attempts to 
increase the net charge of (mostly folded) proteins include chemical modification of 
charged residues on the protein surface and genetic engineering. The latter method 
includes exchange of solvent-exposed amino acids, also known as “supercharging”, 
and increase of the overall charge by means of a highly charged tag. Examples from 
the literature are presented and advantages as well as disadvantages of both methods 
in regard to applications are discussed. A focus is given to polyionic variants of 
genetically engineered, unfolded polypeptides on the basis of elastin and their 
potential as versatile materials for applications in biomedicine and biotechnology 
is highlighted.
Supercharged Proteins and Their Applications in Biomedicine and Biotechnology
9
1. HIGHLY CHARGED PROTEINS IN NATURE
1.1 Highly charged proteins and their functions
Electrostatic interactions play an important role in many intra- and extracellular 
processes in nature. The four charged amino acids lysine, arginine, glutamic acid 
and aspartic acid are present in most naturally occurring proteins and are often 
involved in protein-protein interactions.[1-4] Furthermore, electrostatic attraction 
mediates interactions between proteins and nucleic acids,[5-9] membranes[10-13] or 
small molecules.[14-16] In other cases proteins possess highly charged, surface-
exposed regions to prevent unfavorable interactions that might lead to aggregation.
[17] Analysis of the protein databank SwissProt[18] revealed that most proteins in 
nature are moderately charged. Only five percent of all proteins contained in the 
databank possess one or more uncompensated charges per ten amino acids. Table 1 
summarizes the proteins with the highest net charge density (NCD; column 5), which 
was calculated according to 
NCD = (#posAA - #negAA)/#AA     (1)
with #posAA (#negAA) = number of positively (negatively) charged amino acids and 
#AA = total number of amino acids. For the sake of clarity, only the protein with the 
highest net charge density of a set of similar proteins is listed.
Among the most positively charged proteins in nature are histones, histone-like 
proteins and protamines (Table 1a, entries 1, 5, 6, 7 and 13). Histones are responsible 
for DNA condensation in eukaryotic cells; together with DNA they form the major 
building blocks of chromatin.[19] During the post-meiotic maturation of male haploid 
germ cells, histones are replaced by protamines and transition proteins, small basic 
proteins.[20,21] Sperm protamine P3 of Murex brandaris, a predatory sea snail, contains 
40 positively charged residues on a total length of 54 amino acids, and is the most highly 
charged natural protein contained in the protein databank SwissProt to date. Moreover, 
highly charged proteins are involved in protein synthesis as subunits of the ribosome 
complex (Table 1a, entries 2-4, and Table 1b, entry 4). Other cationic polypeptides 
act as neurotoxins by blocking potassium or sodium channels (entries 14 and 16) or 
are involved in bacterial spore coat formation (entry 15). Furthermore, a number of 
antimicrobial polypeptides like cryptonin[22], misgurin[23] and androctonin[24] can be 
found among highly cationic proteins (entries 9, 11 and 12). Antimicrobial (poly)
peptides (AMPs) comprise a first line of host defense against microbial pathogens in 
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a wide variety of organisms ranging from invertebrates and vertebrates to plants.[25,26] 
Cryptonin was isolated from the Korean blackish cicada, Cryptotympana dubia. It forms 
a linear amphipathic alpha-helix upon binding to negatively charged cell surfaces and 
kills microbial cells by increasing cell permeability, probably due to pore formation.
[22] Misgurin, an AMP from the loach (mudfish) Misgurnus anguillicaudatus, belongs 
to the same structural class of peptides as cryptonin and exhibits antibacterial activity 
by a similar mechanism.[23] Androctonin, a 25-residue peptide with two disulfide 
bridges, was isolated from the hemolymph of the scorpion Androctonus australis 
and was found to be active against a broad spectrum of both gram-positive and gram-
negative bacteria and fungi.[24] Unlike cryptonin and misgurin, androctonin does not 
form pores, but disintegrates cytoplasmic membranes by micellization in a detergent-
like manner.[27,28] AMPs usually do not exhibit significant hemolytic activity, as their 
cationic charge promotes selectivity for negatively charged microbial cytoplasmic 
membranes over zwitterionic membranes of plants and animals.[29,30] Moreover, 
AMPs show broad activity spectra against bacteria and fungi as well as viruses and 
parasites. This makes these compounds promising candidates for the treatment of 
infections where resistance has rendered antibiotics ineffective.[31]
Among the most negatively charged, naturally occurring proteins are prothymosin 
and parathymosin (Table 1b, entries 1 and 13). Both proteins are expressed in a wide 
variety of tissues and cell lines and are believed to have vital housekeeping functions.
[32] Prothymosin alpha is the most negatively charged natural protein in the SwissProt 
protein database with 54 aspartic and glutamic acid residues, 10 lysine and arginine 
residues and a total length of 111 amino acids. Prothymosin alpha is an oncoprotein 
transcription factor and is involved in cell cycle progression and proliferation.
[33] Parathymosin, on the other hand, is associated with early DNA replication.[32] 
It modulates the interaction of the linker histone H1 with the nucleosome, thereby 
inducing chromatin decondensation.[34] Another protein that is involved in chromatin 
modulation is Chz1, a highly negatively charged nuclear chaperone of the histone 
variant H2AZ (Table 1b, entry 6).[35] H2AZ replaces conventional histone H2A in 
budding yeast and is found in close proximity to the promoters of most genes.[36] 
Chz1 aids in the proper incorporation of histones into nucleosomes by shielding 
their positive charge and by blocking crucial surface sites.[36] Furthermore, highly 
negatively charged proteins are involved in transcriptional and translational 
regulation (Table 1b, entries 3, 7 and 15), cell-cycle control (entry 8), ubiquitin-
dependent proteolysis (entry 9), electron transport in mitochondria (entry 10) and 
receptor-mediated endocytosis (entry 12). Other anionic proteins are components of 
calcified shell layers (entry 5) and building blocks of bacteriophage or virion particles 
(entries 11 and 14).  
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1 sperm protamine P3 DNA
condensation
P83213 0.74 54 40 0 Murex brandaris 
(Purple dye murex)




P62945 0.68 25 17 0 Homo sapiens (Human) 
and other organisms




P54025 0.55 22 13 1 Methanocaldococcus 
jannaschii




P62611 0.44 27 13 1 Thermus aquaticus
5 DNA-binding protein DNA
condensation
(suggested)







Q45881 0.42 117 53 4 Coxiella burnetii
7 Histone H1.C8/H1.M1 DNA
condensation





P22613 0.35 54 21 2 Ovis aries (Sheep)
9 Cryptonin antimicrobial P85028 0.33 24 8 0 Cryptotympana dubia 
(Korean horse cicada)
10 Small core protein core protein P69548 0.33 24 8 0 Enterobacteria phage
alpha3
11 Misgurin antimicrobial P81474 0.33 21 9 2 Misgurnus
anguillicaudatus 
(Oriental weatherfish)
12 Androctonin antimicrobial P56684 0.32 25 8 0 Androctonus australis 
(Sahara scorpion)
13 Histone H5 DNA
condensation








P83243 0.30 23 7 0 Tityus obscurus 
(Amazonian scorpion)
15 Spore coat protein G incorporation of 
CotB into spore 
coat (suggested)
P39801 0.30 195 71 13 Bacillus subtilis
16 Mu-conotoxin GIIIB blocks
voltagegated N+ 
channels
P01524 0.27 22 8 2 Conus geographus 
(Geography cone)
Table 1. An overview of the most highly charged, naturally occurring proteins, as derived from the 
protein databank SwissProt. For the sake of clarity, only the protein with the highest net charge density 
of a set of similar proteins is listed.
a) Cationic proteins













1 Prothymosin alpha immune function 
(suggested)
P06454 -0.40 111 10 54 Homo sapiens 
(Human)
2 UPF0473 protein 
Helmi_02360
uncharacterized B0TFZ1 -0.39 89 4 39 Heliobacterium 
modesticaldum 
3 Testis ecdysiotropin 
peptide 1
start or boost 
ecdysteroid synthesis 
in testis of larvae and 
pupae
P80936 -0.38 21 0 8 Lymantria 
dispar 
(Gypsy moth)
4 50S ribosomal protein 
L12P
binding site for factors 
involved in protein 
synthesis




component of organic 
matrix of calcified 
layers of the shell
B3A0Q3 -0.35 396 24 164 Lottia gigantea 
(Owl limpet)
6 Histone H2A.Z-specific 
chaperone chz-1
histone replacement in 
chromatin
Q9P534 -0.35 114 7 47 Neurospora 
crassa 




recycling phases of 
transcription








mitosis and the G1 
phase








Q3ZBR6 -0.31 70 5 27 Bos taurus 
(Bovine) 
and other




P00127 -0.31 147 12 58 Saccharomyces 
cerevisiae 
11 Prehead core 
component PIP
phage particle P03720 -0.31 80 10 35 Enterobacteria 
phage T4






Q03650 -0.31 945 9 301 Trypanosoma 
brucei brucei
13 Parathymosin immune function: 
blocking prothymosin α 
P08814 -0.30 102 16 47 Bos taurus 
(Bovine)
14 Protein 6 virion structural 
protein (suggested)
O70791 -0.30 93 4 32 Rice yellow 
stunt virus




C9XUB3 -0.30 140 6 48 Cronobacter 
turicensis 
*NCD = net charge density
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1.2 Intrinsically disordered proteins
Several of the most highly charged, natural proteins are characterized as natively 
unfolded in solution. Natively unfolded or intrinsically disordered proteins (IDPs) 
are divided into two classes: completely and partly unfolded proteins. The proteins 
of the former class are disordered throughout the entire polypeptide chain and can 
be further divided into proteins with no secondary structure at all, and proteins 
with residual secondary structure, but without any tertiary structure.[37] IDPs are 
generally characterized by a low content of hydrophobic amino acid residues 
and a relatively high percentage of uncompensated charged groups, which leads 
to a large net charge at neutral pH.[37] Folding of these proteins into a compact 
structure is unfavorable due to repelling forces of charges. At the same time these 
forces are not balanced by hydrophobic interactions that would promote folding.[38] 
Consistent with these characteristics, IDPs are often found to be highly resistant to 
heat denaturation, aggregation and chemical denaturation.[39] Table 2 provides an 
overview of proteins with the highest net charge listed in DisProt[40], the databank 
of protein disorder. This databank does not contain all disordered proteins, but 
only those that have been characterized as disordered. Among the most cationic, 
disordered proteins are the protamine variant chicken sperm histone and several 
other histone and non-histone, chromosomal proteins (Table 2a, entries 1 to 4, 6, 
9 and 12). Variants of these proteins were also found among the most highly 
charged proteins in the databank SwissProt (Table 1a, entries 1, 6 and 7). Chicken 
sperm histone, a protamine variant, exhibits the highest charge density with 36 
positive charges and a total length of 62 amino acids. Furthermore, several 
polypeptides with antibacterial activity like non-histone chromosomal protein 
H6, cathelicidin antimicrobial peptide and beta-defensin are disordered (Table 2a, 
entries 6, 13 and 15). It was suggested that cationic antimicrobial peptides adopt 
a secondary structure and become amphiphilic upon interaction with the target 
structure, i.e. the bacterial membrane.[41] Rat prothymosin α was found to be the 
protein with the most negative charge density (-0.38) in the databank DisProt (Table 
2b, entry 1). It is therefore assumed that human prothymosin α, which exhibits a 
slightly higher charge density (-0.40) is disordered as well (Table 1b, entry 1). 
Besides DNA condensation and antimicrobial activity, highly charged, intrinsically 
disordered proteins are involved in fatty acid synthesis, protein synthesis (Table 
2a, entries 8, 11 and 14, and Table 2b, entry 9) and protein degradation (Table 
2b, entries 2 and 7). Furthermore, anionic, disordered proteins are associated with 
mineralization processes (Table 2b, entries 3 and 11), calcium storage (entry 5), 




Table 2. A summary of highly charged, intrinsically disordered proteins, as derived from DisProt[40], the 
databank of protein disorder.












1 Sperm histone 
(protamine)
DNA condensation P15340/ 
DP00057
0.58 62 36 0 Gallus gallus 
(Chicken)
2 Histone H5 DNA condensation P02259/ 
DP00044
0.32 189 66 5 Gallus gallus 
(Chicken)
3 Histone H1.0 DNA condensation P10922/ 
DP00097
0.27 193 62 9 Mus musculus 
(Mouse)
4 Histone H1.2 DNA condensation P15865/ 
DP00136


















0.20 70 20 6 Oncorhynchus mykiss 
(Rainbow trout)
(Salmo gairdneri)




0.18 120 36 14 Aplysia kurodai 
(Kuroda’s sea hare)
8 50S ribosomal 
protein L33
protein synthesis P0A7N9/ 
DP00143

















0.18 169 38 8 Mus musculus 
(Mouse)
11 30S ribosomal 
protein S12
protein synthesis P0A7S3/ 
DP00145
0.17 124 28 7 Escherichia coli
12 Histone H1 DNA condensation P53551/ 
DP00423






antibacterial activity P49913/ 
DP00004 
_C002
0.16 37 11 5 Homo sapiens 
(Human)
14 30S ribosomal 
protein S18
protein synthesis P0A7T7/ 
DP00146
0.16 75 18 6 Escherichia coli
15 Beta-defensin 12 antibacterial activity P46170/ 
DP00209
0.16 38 6 0 Bos taurus 
(Bovine)
*NCD = net charge density
Supercharged Proteins and Their Applications in Biomedicine and Biotechnology
15













1 Prothymosin alpha transcription factor 




-0.38 112 11 53 Rattus norvegicus 
(rat)






-0.31 70 5 27 Homo Sapiens 
(Human)




-0.24 613 70 216 Danio rerio 
(Zebrafish)
(Brachydanio rerio)
4 Cyclic nucleotide-gated 
cation channel beta-1 
[Isoform GARP1]




-0.20 590 46 165 Bos taurus 
(Bovine)




-0.20 395 32 111 Oryctolagus 
cuniculus (Rabbit)
6 Acyl carrier protein fatty acid biosynthesis P0A6A8/ 
DP00416
-0.19 78 5 20 Escherichia coli
7 Prokaryotic ubiquitin-
like protein pup




-0.19 64 7 19 Mycobacterium 
tuberculosis
8 Troponin C, slow 






-0.18 161 17 46 Bos taurus 
(Bovine)
9 60S acidic ribosomal 
protein P1-alpha
protein synthesis P05318/ 
DP00164
-0.18 106 5 24 Saccharomyces 
cerevisiae 
(Baker’s yeast)






-0.17 235 13 53 Canis lupus 
familiaris (Dog) 




-0.17 317 23 76 Homo sapiens 
(Human)




-0.16 149 14 38 Drosophila 
melanogaster 
(Fruit fly)
13 Latent membrane 
protein 2A









cell signaling Q9CQK7/ 
DP00587
-0.16 243 24 62 Mus musculus 
(Mouse)
*NCD = net charge density
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IDPs often play a role in transcriptional and translational regulation (Table 2a, 
entry 7), signal transduction (Table 2b, entries 4, 12 to 14) and cell-cycle control 
(Table 2a, entry 10 and Table 2b, entry 1). This indicates that IDPs are involved 
in processes which require certain flexibility, for example as linkers or as binding 
partners for multiple target structures.[38,42] Furthermore, IDPs are associated with 
a number of diseases such as prion diseases, Parkinson’s disease, Alzheimer and 
Huntington’s disease.[37,42] Both protein aggregation and amyloidosis, the ordered 
aggregation of proteins into fibers, are implicated to contribute negatively to 
the development of these diseases. Interestingly, it was found that mutants of an 
amyloid disease related protein with reduced net charge promote its aggregation.[43] 
These findings suggest that surface charge plays a crucial role in the aggregation 
behavior of proteins.  
2. CHANGING THE NET CHARGE OF PROTEINS
So far, natural proteins with high net charges and their functions in nature have 
been discussed. In particular, intrinsically disordered proteins were highlighted. 
In the context of IDPs that are associated with amyloidosis, it was mentioned that 
protein aggregation is closely linked to surface charge. Aggregation of proteins can 
be induced by changing the pH, the composition of a solution or by a temperature 
increase. Although protein aggregation is desired under certain circumstances, it 
is highly unfavorable in most cases, because it often results in irreversible protein 
inactivation. This poses a problem in biotechnology where enzymes are used as 
catalysts for chemical reactions in industrial processes and as additives in washing 
powders. These processes usually take place under conditions that promote 
protein aggregation like elevated temperature, addition of organic solvents and 
high concentrations of surfactants.[44] Consequently, strategies were developed 
to influence the aggregation behavior of proteins.[45] One strategy is to increase 
a protein’s net charge, which increases the repellence of partly unfolded chains 
and makes protein aggregation unfavorable. To this end, several methods for 
introducing charges into proteins are described and will be discussed regarding 
their effectiveness and applicability. Furthermore, possible applications of highly 
charged proteins will be described.  
2.1 Post-translational, chemical modification
A simple, inexpensive way of changing the net charge of a protein is the post-
translational, chemical modification of solvent-exposed amino acid residues. 
Supercharged Proteins and Their Applications in Biomedicine and Biotechnology
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Methods like acetylation and succinylation of lysine residues as well as amidation 
of carboxylic groups date back to the late 1960s (Figure 1).[46-49] Although initially 
employed for the characterization of proteins, these methods gained increased 
attention in the following decades due to their effect on protein net charge, which 
alters a protein’s solubility and interaction with oppositely charged molecules.[50-
54] Acetylation of lysine e-amino groups, for example, decreases the number of 
positive charges and thereby leads to variants with a higher net negative charge 
(Figure 1, pathway 1).
By reaction with acetic anhydride, Shaw et al. created highly negatively 
charged variants of bacterial a-amylase, an industrially relevant hydrolase, 
without perturbing its structural integrity or decreasing its thermostability.[55] The 
modified variant with approximately 17 acetyl modifications proved to be more 
resistant to irreversible inactivation and aggregation in the presence of anionic and 
Figure 1. An overview of post-translational, chemical modifications of proteins. The net 
charge of a protein can be increased by elimination (1, 3) or inversion (2, 4) of charges. 
Amine groups are neutralized by acetylation (1) or their charge is reversed by succinylation 
(2). Amidation (3) of carboxyl groups eliminates negative charges on the protein surface. In 
the special case of amination (4), a positively charged group is introduced instead.
Chapter 1
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neutral surfactants that are commonly used in industrial applications.[56] However, 
acetylation of lysine residues simultaneously increases the hydrophobicity of the 
protein surface and can even reduce the stability of a protein towards denaturants 
and/or heat, which was shown for the enzyme bovine carbonic anhydrase.[57] 
Similarly, it was demonstrated that ovalbumin was more prone to urea and heat-
induced unfolding after amidation of its carboxyl groups.[58,59] As an alternative 
to neutralization, charges of residues can be reversed. This increases the net 
charge of the protein, and at the same time the generation of a more hydrophobic 
protein surface is avoided. Upon reaction with succinic anhydride, lysine e-amino 
groups are converted from basic to acidic groups (Figure 1, pathway 2).[48,54] 
Interestingly, succinylation of lysine residues was also shown to greatly enhance 
the activity of cyclodextrin glycosyltransferase from Thermoanaerobacter.
[60] However, like acetylation, succinylation might lead to destabilization and 
increased aggregation of the modified protein.[58,59,61] The underlying mechanisms 
of destabilization have not been fully elucidated yet. It was suggested that charge 
modification might interfere with the ion pair network, thereby destabilizing the 
protein structure.[59] This statement is in line with the finding that protein stability 
after succinylation seems to be dependent on the number and sites of modification(s).
[54]
Instead of creating highly anionic variants by reversing the charge of lysine, 
proteins can be cationized by substituting carboxylic groups with amine groups 
(Figure 1, pathway 4).[50] As carboxylates are less reactive than amine groups, 
activation of the carboxylic acid group by a carbodiimide needs to be performed 
before reaction with the diamine takes place. Several proteins, like ferritin, catalase, 
superoxide dismutase, bovine serum albumin (BSA) and ovalbumin, were modified 
by amidation to increase their interaction with negatively charged tissues.[50,51] It 
was found that cationized enzymes were much longer retained in cartilaginous tissue 
than their natural counterparts and their anti-inflammatory effect was prolonged.[51] 
Cationization does not only promote adhesion to tissues and cell membranes, but 
can stimulate uptake of the modified proteins by cells. Cationized BSA (cBSA) 
was taken up by isolated bovine brain microvessels in vitro and was shown to pass 
the blood-brain barrier in vivo after carotid infusion in rat models.[62] These 
findings raised expectations that cationized proteins might initiate the uptake of 
biologically active materials like drugs, DNA or proteins. Indeed, cBSA coupled to 
liposomes induced endocytosis by brain capillary endothelial cells via a caveolin-
associated pathway.[63] Furthermore, cBSA was found to form polyplexes with 
plasmid DNA and to efficiently transfect A-549 human epithelial cells in vitro.
[64,65] Biocoatings of cBSA variants promoted immobilization of lipid vesicles and 
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formation of bacterial biofilms.[66,67] In order to stimulate adhesion of mammalian 
cells in vitro, cyclic derivatives of the arginine-glycine-aspartate (RGD) sequence 
were grafted to cBSA.[67] Coatings of these RGD-cBSA derivatives on glass surfaces 
were shown to support cell-matrix adhesion of fibroblast cells.[68]
Taken together, chemical modifications can be used to change a protein’s overall 
charge and to decrease unfavorable interactions in order to increase aggregation 
resistance. Alternatively, favorable interactions with oppositely charged molecules 
and structures can be enhanced, thereby promoting adhesion or even uptake of 
biologically active molecules into cells. Although chemical modification of 
charged, solution-exposed residues is a simple method to change a protein’s 
net charge, its applicability needs to be evaluated for individual proteins. 
Furthermore, chemical modification results in a mixture of variants with 
different net charges and modification patterns. To yield fractions with a narrow 
net charge distribution, an extra purification step needs to be performed.[64] 
This method is therefore favorable in cases where the protein is directly extracted 
from its natural source. For proteins that are produced in a heterologous host 
organism, however, the gene encoding for the protein is already available in 
the respective vector, and surface charges are easily modified by genetic 
engineering. This method results in well-defined protein variants and therefore 
presents an elegant alternative to chemical modification as described in the 
following paragraph. 
2.2 Modification of solvent-exposed amino acids by genetic mutation
The genetic engineering approach to dramatically increase a protein’s net charge was 
first exploited by Liu and co-workers in 2007 and was referred to as “supercharging 
of proteins”: charged, solvent-exposed amino acids were identified by analysis of the 
crystal structure and modified by genetic mutation.[69] Negatively charged residues 
(aspartic and glutamic acid) were exchanged by positively charged amino acids 
(lysine and arginine) and vice versa to create “superpositive” and “supernegative” 
variants, respectively (Figure 2). 
With this strategy, the net charge density of a superfolder variant of green 
fluorescent protein (sfGFP) was tuned between -0.12 and +0.19 (as shown in Table 
3). These supercharged GFPs retained their fluorescence and exhibited circular 
dichroism spectra similar to stGFP, indicating that proper folding of the protein 
was not impaired by the mutations that had been introduced. More interestingly, 
GFP(+36) and GFP(-30) showed extraordinary aggregation resistance: both 
variants remained soluble when heated to 100 °C and recovered significant 
fluorescence upon cooling.[69] Liu and co-workers also demonstrated that a 
Chapter 1
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negatively supercharged variant of glutathione-S-transferase (GST) exhibited 
catalytic activity similar to wild-type GST (wtGST) and retained 40% of its 
catalytic activity after heating to 100 °C and subsequent cooling, while wtGST 
was irreversibly aggregated and its activity reduced to zero.[69] Like cBSA, a 
superpositively charged GFP variant carrying 36 positive charges (+36GFP) 
readily penetrated several mammalian cell types by an endocytotic pathway.[70] 
Cationized GFP was therefore expected to likewise complex with nucleic acids 
and to mediate their transport into mammalian cells. +36GFP formed complexes 
with and delivered silencing RNA (siRNA) into various cell lines, causing 
gene silencing.[70] Moreover, fusion proteins containing +36 GFP rapidly and 
potently penetrated mammalian cells in vitro without toxicity and were able 
to access the cytosol.[71] A +36 GFP fusion to Cre recombinase effected 
recombination in transiently transfected HeLa cells in vitro and in mouse retinal 
cells in vivo.[71] 
Considering that thermostability of proteins from thermophilic and 
hyperthermophilic organisms is in part conveyed by salt bridges between 
charged amino acid residues on the protein surface, it is somewhat surprising 
that thermoresistance can be achieved by exhaustive supercharging of folded 
proteins.[72-75] Reversing solvent-exposed charges that are employed in electrostatic 
interactions leads to a decrease in thermostability due to intramolecular repulsion, 
which might not be balanced by the gain in thermostability. This might explain why 
some designs for supercharged variants were not functional or failed to express.[69] 
Elimination of favorable interactions or introduction of unfavorable interactions 
might also be the reason why post-translational, chemical modification results in 
increased aggregation in some cases. Based on these considerations, Miklos et al. 
Figure 2. Positively (blue) and negatively (red) supercharged GFP variants created by genetic 
engineering from a superfolder variant (sfGFP). Reproduced from ref.[70]. 
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used a structure-based computational design to create thermoresistant single-chain 
Fv antibody fragments (scFvs).
[76] In this approach, the energetic consequences 
of each amino acid substitution were considered for the design of positively and 
negatively supercharged scFv variants. Of all expressed and purified variants, three 
positive variants with net charge densities between +0.06 and +0.09 displayed 
strong binding to the antigen and at the same time moderate to high thermal stability 
(Table 3). For comparison, a series of supercharged scFv variants was created based 
on the approach of Liu’s group, which all failed to be thermoresistant.[76]  These 
results demonstrate that the supercharging approach yields functional variants only 
of certain proteins, whereas for other proteins the more elaborate rational design 
approach has to be applied.
An alternative to rational design is the creation of a library of supercharged 
variants combined with simultaneous screening for the desired property and for 
function preservation. The group of Weiss used this alternative strategy for the 
solubilization of the membrane protein caveolin.[77] In order to fully elucidate 
structure, function and interacting factors of a membrane protein, relatively large 
amounts of the respective protein are required. To this end, heterologous production 
Table 3. Genetically engineered, supercharged proteins
*NCD = net charge density. #NCD was only calculated for the intra-membrane domain (IMD), as it was 
not clear from the given information in ref. [77] which caveolin variant was used.
Protein Name NCD* length (#AA) # posAA # negAA net charge
1 -30GFP -0.12 248 19 49 -7
2 -25GFP -0.10 248 21 46 -30
3 sfGFP -0.03 248 27 34 -25
4 +36GFP +0.15 248 56 20 +36
5 +48GFP +0.19 248 63 15 +48
6 scFv anti-MS3 +0.02 233 24 19 +5
7 scFv anti-MS3 (K-pos-1) +0.06 233 32 19 +13
8 scFv anti-MS3 (K-pos-2) +0.07 233 35 19 +16
9 scFv anti-MS3 (K-pos-3) +0.09 233 38 18 +20
10 wild type caveolin (IMD#) 0 33 0 0 0
11 caveolin selectant 11 (IMD#) +0.03 33 5 4 1
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is a highly suitable method. However, membrane proteins either contain one to 
several hydrophobic transmembrane segments or amphiphatic β-strands. Since their 
hydrophobicity renders them prone to aggregation in aqueous environment they 
cannot be overexpressed in the cytoplasm, but have to be targeted to the membrane. 
Consequently, protein yields are low. To overcome this bottleneck in membrane 
protein research, a two-step phage display assay was developed, as it allows for 
screening of a large library of variants: in the anti-selection step hydrophobic variants 
were removed by binding to resin, whereas in the positive selection step functional, 
folded variants which were bound to the caveolin ligand HIV gp41 (cavin) were 
selected (Figure 3). 
Figure 3. A two-step phage display for the selection of a functional, soluble, full-length 
variant of the membrane protein caveolin. A single phage contains the gene encoding for a 
protein variant and at the same time displays the protein on its surface. In this way, the genetic 
information is co-selected with the protein variant that carries the desired properties. Adapted 
from ref. [77]. 
By this method a functional, soluble, full-length caveolin variant was selected 
from the library (Table 3). This variant was successfully objected to direct interaction 
studies of caveolin and its ligand cavin.[77]
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It can be concluded that rational design considering intramolecular interactions or 
a concept with direct selection for desired property as well as function is preferable to 
random supercharging of solvent-exposed amino acids.
2.3 Supercharging by means of a highly charged peptide tag
All methods discussed so far rely on modification of the protein itself. Alternatively, a 
highly charged tag can be attached to a protein of interest in order to increase its overall 
charge. This method bears the advantage that the protein itself remains unchanged and 
therefore obviates the need for rational design or extensive screening for functional 
variants. Negatively supercharged tags are used to significantly enhance the stability 
of proteins in solution.[78-80] Examples are the protein G B1 domain (Table 4, entry 1), 
the protein B domain of bacteriophage T7 (T7B; entry 2) and its more acidic variant 
T7B9 (entry 3) as well as the acidic tail of synuclein (ATS; entry 4).[78-80] Fusion 
of these anionic peptides to aggregation-prone proteins prevented their aggregation 
during overexpression and provided sufficient solubility for structural and biological 
investigations.[78,79,81] Moreover, highly charged peptide extensions can significantly 
enhance stability and solubility of protein formulations for therapeutic purposes. 
Introduction of an acidic peptide derived from the C-terminal tail of synuclein 
(ATS) into three different therapeutic proteins (human growth hormone, granulocyte 
colony-stimulating factor and human leptin) resulted in higher stability against heat, 
agitation and freeze/thawing cycles in vitro, as well as improved pharmacokinetics 
in vivo (Table 4, entry 4).[80] Interestingly, anionic stabilizing tags vary considerably 
in their net charge density (from -0.07 to -0.41), but only moderately in their number 
of negative charges (from 9 to 14), indicating that their stabilizing effect is more 
dependent on the number of charges than on the charge density.    
Positively supercharged (poly)peptides mainly belong to the group of cell-
penetrating peptides (CPPs).[82] CPPs like oligo-arginine and HIV-TAT can trigger 
the transport of fusion proteins across membrane barriers and deliver them to the 
cytoplasm or other cellular compartments (Table 4, entries 5 and 6).[83,84] Recently it 
was shown that also naturally supercharged, cationic human protein fragments are 
able to stimulate uptake of proteins into mammalian cells in vitro and in vivo (Table 4, 
entries 7-9).[85] These human protein fragments have a much lower net charge density 
(0.2 vs. 0.5 to 1) than the very short peptides R9 and HIV-TAT, but comparable to the 
superpositive +36GFP (NCD = 0.15; entry 11). Despite their variation in length (from 
9 to 248 amino acids), all these (poly)peptides were shown to penetrate cells and to 
deliver fusion proteins to the cytoplasm, indicating that size alone is not a critical 
parameter for uptake.[70,71,83-85] 
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3. ELASTIN AND ELASTIN-LIKE POLYPEPTIDES
3.1 Sequences and properties of elastin-like polypeptides
In the first parts of this chapter it was discussed how proteins can be supercharged 
by post-translational, chemical modification or genetic engineering. Furthermore, 
we elaborated on highly charged proteins and their role in nature, with a focus on 
intrinsically disordered proteins. The last part of this chapter will focus on elastin-like 
polypeptides (ELPs), a class of intrinsically disordered proteins. Unlike most other 
disordered proteins they are not naturally occurring, but chemically synthesized or 
genetically engineered. Their sequences are based on the elastic parts of elastin, a 
component of the extracellular matrix in vertebrates.[86]  The elastic parts contain 
repetitive sequences with repeats of four to six amino acids that are rich in valine (V), 
proline (P), glycine (G) and alanine (A).[87] ELPs that consist of VPGG, VPGVG or 
VAPGVG repeats are the most intensely studied.[88] Poly(VPGVG) or recombinant 
(VPGVG)n is considered the model sequence for ELPs.
[89] Pioneers in the synthesis 
of ELPs were Urry and colleagues, who discovered that ELPs exhibit a characteristic 
temperature-dependent transition behavior. By heating ELPs in aqueous solution 
above their lower critical solution temperature (LCST), their conformation changes 
from a soluble random-coil to an insoluble ß-spiral, which is formed by regularly 
Protein Name NCD* length (#AA) # posAA # negAA
net 
charge 
1 B1 domain of protein G -0.07 56 6 10 -4
2 T7B -0.11 44 5 10 -5
3 T7B9 -0.25 44 3 14 -11
4 ATS -0.41 22 0 9 -9
5 oligo-arginine (R9) +1.00 9 9 0 +9
6 HIV-TAT protein +0.54 13 7 0 +7
7 ß-defensin 3 (fragment) +0.24 45 13 2 +11
8 c-Jun bZIP domain +0.21 62 19 6 +13
9 histone methyl transferase  (fragment) +0.21 72 18 3 +15
10 +36GFP +0.15 248 56 20 +36
Table 4. Supercharged protein tags for solubilization or uptake of proteins
*NCD = net charge density
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recurring type II ß-turns.[90-94] Urry and co-workers studied the influence of different 
guest amino acids in ELPs that are comprised of the pentapeptide sequence VPGXG. 
They observed that the fourth position (X) can be exchanged by any naturally 
occurring amino acid except proline. The LCSTs of the resulting ELPs reflected the 
hydrophobicity scale of the amino acids, such that the LCST dropped with increasing 
hydrophobicity of the guest residue.[95,96] The first ELPs were chemically synthesized, 
i.e. with limited control over chain length and composition.[92,97] About ten years later 
the emergence of genetic engineering techniques allowed recombinant production of 
ELPs with precise length and composition.[98-102] However, the first cloning strategies 
created sets of ELP genes with a statistical length distribution and thus no guarantee 
for a defined gene length. Therefore Chilkoti and co-workers developed the “recursive 
directional ligation” method, which allows controlled, stepwise oligomerization of a 
monomeric ELP gene containing a defined number of repeats (Figure 4). 
Figure 4. Recursive directional ligation for the oligomerization of elastin-like polypeptides. 
RE: restriction enzyme.  Adapted from ref. [103].
Two monomer genes are ligated to create a dimeric gene. Due to the choice of 
the restriction sites flanking the gene monomer, the restriction site at the seam of the 
monomers is erased during ligation, whereas the restrictions sites at the termini are 
preserved. This allows for the dimer to be used in another round of restriction and 
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ligation, leading to a tetramer, which in turn can go through another round. By varying 
the monomer length and by repeating multiple rounds of restriction and ligation, 
oligomers of theoretically any desired length can be created in a controlled fashion. 
Besides precise control over length and composition, genetic engineering also 
opened up the possibility to create fusion variants of ELPs and proteins with biological 
activity, which substantially increased the applicability of ELPs in biotechnology 
and medicine.[104] Schemes for the purification of proteins and DNA on the basis of 
ELPs were developed and optimized by several groups.[104-109] Furthermore, ELPs 
were employed for targeted delivery of therapeutic peptides,[110-112] small molecule 
drugs, [113-116] proteins,[117] and DNA[118]. Finally, ELPs might find applications as 
hydrogels for tissue engineering[119-123] and controlled release [124] of therapeutics. 
3.2 Ionic ELPs
As mentioned before, the fourth position of the pentapeptide repeat in ELPs can be 
exchanged by any amino acid except proline. This opens up possibilities to create 
variations of ELPs with properties tailored for desired applications. It was already 
pointed out that the guest amino acids greatly influence the hydrophobicity of the 
polypeptide chain. By carefully choosing the guest amino acids, it is possible to fine-
tune the LCST of ELPs in a range between -90 and +250 °C.[95] The greatest increase 
in Tt is achieved by introducing positively or negatively charged amino acids along 
the polypeptide chain, i.e. by creating ionic ELPs.[97,125-128] For an ELP of 81 kDa with 
lysine as a guest residue in every fifth repeat, for example, Tt is above 100 °C in a 
buffered solution of pH 7.[127] Moreover, protonation or deprotonation of the functional 
group determines whether a residue is charged or not. Thus, charged residues add pH 
responsiveness to ELPs. For the aforementioned cationic ELP, Tt drops from above 
100 °C at pH 7 to 28 °C in basic conditions (0.1 N NaOH), as the ε-amine groups 
of the lysine residues become deprotonated, i.e. non-charged.[127] Furthermore, 
charged residues are able to electrostatically interact with counterions in solution, 
thereby reducing repelling forces between charges and drastically decreasing Tt. As 
a consequence, ionic ELPs are more sensitive to changes in salinity than ELPs with 
only aliphatic amino acids.[125-127] An overview of Tt for different ELP constructs at 
various conditions is given in Table 5. Taken together, by introducing charged amino 
acids, smart ELPs can be generated that are highly responsive towards changes in 
both pH and salinity. 
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The outstanding properties of these materials promoted their application in 
biotechnology and biomedicine. The stronger salt dependency of the cationic 
ELPs compared to purely aliphatic ELPs was exploited for improved purification 
of recombinant proteins.[131] Furthermore, introduction of charged amino acids into 
ELP sequences modifies their response to hydrophobic and hydrophilic surfaces, 
which was exploited for the formation of regularly shaped and equally distributed 
nanopores[132] and the fabrication of nanosized gold crystals as stimuli-responsive 
sensors and detectors in biological systems.[133] Next to their responsiveness, the 
precise incorporation of ionic guest residues in terms of their position, frequency and 
nature provides outstanding possibilities to crosslink or anchor functional moieties 
ELP MW [kDa]




(φ=V, ca. 86%;  
φ=K, ca. 14%)
n.d. n.d. n.d. n.d. 0.03 [97]
[(VPGVG)4 (VPGKG)]39 81.1 28 
a) >100 b) 50 c) 0.050 [127]
[VPGKG(VPGVG)6]n, 
(n = 8, 16, 32)
23.9, 47.1, 93.4 - 60, 45, 39 d) 30, 22, 19 e) 0.033 [126]
[VPGKG(VPGVG)16]n
(n = 8, 16, 32)
21.7, 42.7, 84.8 - 45, 34, 30 d) 26, 19, 15 e) 0.012 [126]
[VPGKG(VPGVG)2VPGFG]n
(n = 4, 8, 16, 32)
7.7, 14.6, 28.3, 
55.7
-, -, -, 20 f) -, -, 61, 43 d)  -, -, 17, 11 e) 0.050 [125]
[VPGKG(VPGVG)7VPGFG]n
(n = 2, 4, 8, 16)
8.4, 15.9, 31.0, 
61.1
-, -, -, 15 f) -, 48, 35, 
26 d)





(φ=V, ca. 80%;  φ=G, ca. 20%)
n.d. n.d. n.d. n.d. 0.04 [97]
poly[IPGφG]
(φ=V or E; various ratios)




(φ=V or D; various ratios)




(n = 5, 9, 15, 30, 45)
10.4, 18.7, 31.2, 
62.3, 93.5 g)
31.5, 25.5, 23, 
21, 20.5 h)
n.d. n.d. 0.040 [128]
Table 5. Transition temperatures (Tt) of cationic and anionic ELP under various conditions.
*NCD = net charge density. a) 0.1 M NaOH; b) 50 mM TrisHCl, pH 7.0; c) 150 mM NaCl (, 50 mM TrisHCl, pH 7.0); d) PBS; e) 
PBS, 1M NaCl; f) 20 mM phosphate buffer, pH 12; g) calculated; h) phosphate buffer (pH 2.5)
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to the polymer backbone.[97,115,127] Due to their sequence similarity to human elastin, 
hydrogels from ELPs are promising candidates as matrices for tissue engineering in 
vitro. Cross-linking leads to stiffening of ELP hydrogels and resistance to harsher 
conditions and was therefore applied to gels which were tailored for in-situ gelation 
or as matrices for tissue engineering in vitro.[125,126,134-137] Moreover, recombinant ELPs 
have the advantage that functional domains can be incorporated directly into the 
polypeptide sequence by genetic engineering. In this way, cell attachment sequences 
or protease target sequences for facilitated bioprocessability can be inserted without 
the need of any further coupling step.[138] 
As shown so far, most applications exploit the increased pH and salt sensitivity 
upon introduction of ionic residues into ELPs or use these residues as anchoring 
moieties for chemical reactions. Few publications on ionic ELPs actually take 
advantage of electrostatic interactions for the (self-)assembly of supramolecular 
structures. A widely known technique is the so-called layer-by-layer (LbL) technology: 
Oppositely charged polyelectrolytes are consecutively deposited on a flat or spherical 
surface to build up multi-layer coatings.[139] The group of Rodríguez-Cabello used a 
peptide sequence rich in aspartic acid, glutamic acid and arginine flanked by cationic 
ELP sequences for the build-up of multiple layers with chitosan, a polysaccharide 
composed of β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine.[140] Due to 
the fact that chitosan is positively charged at a pH below 6, the authors concluded 
that negatively charged sequences were employed for the electrostatic interaction 
between layers.[140] The same concept was used for thin coatings of cationic ELPs 
on chitosan. The ELP sequences flanked a short RGD sequence for enhanced cell 
adhesion and proliferation.[141] However, a similar sequence with purely aliphatic 
ELPs flanking RGD and a triple-lysine tag at the N-terminus also absorbed with 
chitosan in a sequential fashion. This indicates that electrostatic interactions did not 
seem to play a crucial role in the layer assembly of this system.[142] 
To the best of our knowledge, there is only one case reported in literature apart 
from the work described in this thesis where electrostatic interactions were the primary 
force for supramolecular assembly of an ionic ELP sequence and an oppositely 
charged polymer or of two oppositely charged ELP sequences. For deposition on a flat 
surface, Golonka et al. used cationic and anionic ELPs, where every fifth pentapeptide 
contained a charged residue (either lysine or glutamic acid).[143] Due to the fact that 
the guest residue in all other repeats was isoleucine, which is more hydrophobic 
than valine, the deposited film still showed temperature-responsive collapsing and 
swelling upon temperature cycling between four and 40 °C. In the collapsed state 
the films were shown to be stable upon prolonged (72 h) incubation at close-to 
physiological conditions (0.1 M NaCl and 37 °C).[143] This example demonstrates that 
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ionic ELPs are versatile protein polyelectrolytes that might serve as building blocks 
in a variety of electrostatically assembled structures.
4. SUMMARY
In nature, highly charged proteins interact with a variety of biomacromolecules 
and structures like membranes via electrostatic forces. They are involved in DNA 
condensation, gene expression modulation and protein translation, or exhibit 
antibacterial activities by interacting with bacterial cell membranes. Furthermore, they 
are often resilient to aggregation at higher temperatures due to charge repulsion. By 
increasing the net charge of moderately charged proteins, their aggregation behavior 
can be tuned and their stability towards elevated temperatures and denaturants can 
be increased. Moreover, cationized proteins were shown to form complexes with 
negatively charged polynucleotides (DNA and RNA) and liposomes. They interact with 
bacterial and mammalian cell membranes and efficiently induce the uptake of nucleic 
acids and fusion proteins by mammalian cells in vitro and in vivo. Post-translational, 
chemical modification of surface-exposed amino acids represents a quick and simple 
method to increase a protein’s net charge. Examples of chemically supercharged 
proteins exhibiting higher stability towards denaturation are reported in literature and 
were discussed in this chapter. However, chemical modification can also lead to loss 
of structural integrity and/or function.  Furthermore, its heterogeneous nature makes 
elaborate reaction and purification schemes necessary to obtain well-characterized 
samples with narrow net charge distribution. Therefore, chemical modification is 
advantageous in cases where the protein of interest is directly extracted from its 
natural source and where an exactly defined product is not required. In contrast to 
chemical modification, genetic engineering allows for precise control over the amount 
and positions of modified residues on the protein scaffold. Exhaustive supercharging 
of solvent-exposed amino acids yielded functional, highly thermostable variants of 
different proteins. However, this method might also destroy stabilizing salt bridges 
and result in loss of stability and function. Depending on the protein, supercharging 
requires rational design, taking into account the microenvironment of surface charges 
and their interactions, or simultaneous screening for functionality and increase in 
net charge. Alternatively, the net charge of a protein can be increased by fusion to a 
supercharged tag. In the case of elastin-like polypeptides, elaborate rational design or 
screening is not required for supercharging, as these proteins are naturally unfolded 
and their repetitive sequence allows for the incorporation of charged amino acids at 
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6. MOTIVATION AND THESIS OVERVIEW 
The goal of the work described in this thesis was to fabricate supercharged, unfolded 
proteins of varying lengths and unprecedented charge density and to evaluate their 
applicability in biomedicine and nanotechnology. As a starting point for the design 
of these proteins elastin-like polypeptides (ELPs) were chosen. ELPs are tunable, 
mono-disperse materials with outstanding properties (in particular biocompatibility 
and bioprocessability) for applications in biotechnology and medicine such as tissue 
engineering, scaffolds for in-situ repair and drug delivery systems. Ionic ELPs were 
designed by introducing charged amino acids as guest residues along the polymer 
backbone to further enhance the tuneability of the temperature-dependent ELP 
response to salinity, pH change and surface hydrophobicity. However, only few charged 
residues were incorporated into the polypeptide chain. We decided to further explore 
the applicability of ELPs by exchanging the aliphatic amino acids at the fourth position 
with the charged amino acids lysine or glutamic acid in nine out of ten pentapeptide 
repeats, thereby creating cationic and anionic supercharged variants of much higher 
charge density than reported before. Chapter 2 describes the design and expression of 
these supercharged, unfolded polypeptides (SUPs). The protein polyelectrolytes were 
monodisperse and had a precisely defined amino acid composition, sequence and 
stereochemistry. Furthermore, cytotoxicity assays revealed that positively charged 
SUPs are considerably less cytotoxic than cationic polyelectrolytes commonly used 
for biomedical applications. Considering their polyelectrolyte nature we assumed 
that SUPs might be transferred into electrostatically assembled superstructures. It is 
well known that electrostatic assemblies can be fabricated from oppositely charged 
polyelectrolytes using the layer-by-layer technique. This technique was employed to 
create capsules composed of SUPs. These capsules were stable after core removal, 
showing that the charge density of the SUPs was sufficient to maintain capsule wall 
integrity. 
Encouraged by these findings, we decided to assess the interaction of cationic 
SUPs with naturally occurring polyelectrolyte films and investigated their effect 
on the properties of these films. Salivary conditioning films (SCFs) were chosen as 
an example because of their biomedical relevance. Highly glycosylated, negatively 
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charged proteins, so called mucins, are mainly responsible for the lubricating 
properties of SCF in the mouth. To provide efficient biolubrication, these mucins 
have to be constantly replenished by saliva flow. In patients with dry-mouth disease 
saliva flow is dramatically decreased, leading to increased friction between surfaces 
and pain during speaking and mastication. The question arose whether cationic SUPs 
(CSUPs) are able to electrostatically interact with the negatively charged mucins, 
thereby stabilizing the SCF. In-vitro experiments demonstrated that cationic SUPs 
indeed interact with SCF, as described in detail in chapter 3. This interaction resulted 
in increased rigidity of the film and consequently in lower friction forces. However, 
efficient biolubrication is not only dependent on film rigidity; structural integrity 
at higher normal friction forces has to be maintained as well. It was observed that 
structural integrity is strongly dependent on the length of the CSUP, as only SCF 
treated with a high molecular weight CSUP variant maintained integrity, whereas 
untreated film and SCF treated with a shorter variant failed at higher normal forces. 
Concluding, it was shown in chapter 3 that treatment of SCF with the long CSUP 
variant can increase its resistance against interfacial shear stress and damage. As an 
additive to mouth sprays that are routinely prescribed for the treatment of dry-mouth 
disease, CSUPs might greatly improve the duration of effect and substantially reduce 
dryness perception.  
In addition to their low toxicity, SUPs surpass other polyelectrolytes in regard 
to functionalization. Genetic engineering provides the possibility to fuse SUPs to 
a protein carrying a (biological) function, thereby obviating the need of an extra 
conjugation step after production. As a proof-of principle, SUPs were designed 
as fusion proteins with green fluorescent protein (GFP). Chapter 4 describes the 
successful expression and purification of GFP-SUP fusion variants carrying between 
-144 and +72 charges in the SUP part. The supercharged tag can be employed to 
equip electrostatic assemblies with a function, in this case fluorescence. Capsules 
were prepared according to procedures described in chapter 2, but this time one layer 
was composed of GFP fused to a SUP with 72 positive charges. Due to the intrinsic 
fluorescence of GFP, uptake of the capsules by cells and their intracellular fate could 
be followed by fluorescence microscopy. Applying this principle, other functions like 
enzymatic activity or ligands for targeted delivery can be introduced to capsules, 
complex coacervate micelles and other superstructures.
Supercharged protein tags can not only be exploited for functionalization of 
electrostatically assembled structures; they might also greatly enhance recognition of 
proteins in detectors that rely on changes in the electric field. In chapter 5 cationic and 
anionic GFP-SUPs with different lengths of the ELP block, i.e. various amounts of 
charges, were compared regarding their performance in devices for protein detection 
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based on nanowire field-effect transistors. It was found that the response was clearly 
dependent on the sort of charge. Binding of cationic GFP-SUPs to the immobilized 
receptor on the nanowire surface resulted in a conductivity decrease, whereas anionic 
GFP-SUPs increased conductivity. Already short SUP tags with nine positive or 
negative charges were sufficient to induce a change in nanowire conductivity upon 
binding of the GFP part, whereas binding of GFP without a charged tag could not 
elicit a signal. In general, cationic SUP tags performed better than anionic tags. 
Further research is required to determine the optimum tag length, but the preliminary 
results confirm that SUP tags indeed enable recognition of GFP in nanowire field-
effect transistors.
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Chapter 2
De Novo Design of Supercharged, Unfolded 




Here we report for the first time the design and expression of highly charged, 
unfolded protein polymers based on elastin-like peptides (ELPs). Positively and 
negatively charged variants were achieved by introducing lysine and glutamic acid 
residues, respectively, within the repetitive pentapeptide units. Subsequently it was 
demonstrated that the monodisperse protein polyelectrolytes with precisely defined 
amino acid compositions, sequences and stereochemistries can be transferred into 
superstructures exploiting their electrostatic interactions. Hollow capsules were 
assembled from oppositely charged protein chains by using the layer-by-layer 
technique. The structures of the capsules were analyzed by various microscopy 
techniques revealing the fabrication of multilayer containers. Due to their low 
toxicity in comparison to other polyelectrolytes, supercharged ELPs are appealing 
candidates for the construction of electrostatically induced scaffolds in biomedicine.
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Genetically encoded polypeptides with repetitive motifs have gained increasing 
attention in recent years due to their high potential for biotechnological and biomedical 
applications. This development was mainly fueled by progress in recombinant DNA 
technology allowing precise control of the structure of the resulting macromolecules.
[1,2] Important examples are silk-like,[3] collagen-like[4,5] and elastin-like proteins 
(ELPs)[6]. The latter are derived from a repeating motif within a hydrophobic domain 
of mammalian tropoelastin. The most common pentapeptide motif has the sequence 
(VPGXG)n with X being any guest amino acid except proline and n denoting the 
number of repeats.[7] The structural and physical properties of ELPs, such as their 
elastic/mechanical as well as thermoresponsive behavior, have been investigated.[8-10] 
Their ability to undergo a reversible phase transition at the so-called lower critical 
solution temperature (LCST) has been exploited for the purification of proteins[11] and 
DNA.[12] For tissue engineering purposes, ELPs were designed as thermally sensitive 
hydrogels that solidify when injected into the body.[13] Furthermore, their temperature 
responsiveness was utilized for drug delivery applications. In hyperthermia treatment, 
ELPs were accumulated in tumors[14] and the LCST-behavior was employed to induce 
micelle formation of block ELP structures.[15]
RESULTS AND DISCUSSION
Design, Preparation and Characterization of Elastin-like Polypeptides
The choice of different guest amino acids within the ELP motif allows the precise 
control of LCST and the incorporation of chemical modifications.[16] Here, we took 
advantage of the flexibility of amino acid composition at the fourth position within 
the repeat to transform ELPs into unprecedented highly charged anionic and cationic 
polyelectrolytes. These structures of biosynthetic origin are much better defined than 
their chemically synthesized counterparts. To assess their viability in a common 
application for polyelectrolytes in a biomedical context, these materials were 
transformed into superstructures, i.e. hollow capsules, employing the electrostatic 
interactions of oppositely charged variants.
We thus decided to introduce lysine and glutamic acid residues in order to obtain 
highly positively and negatively charged polypeptide chains, respectively. Monomer 
units of the ELP gene encoded nine to twelve pentapeptide repeats (Val-Pro-Gly-Lys/
Glu-Gly) and were multimerized using recursive directional ligation, as described by 
Chilkoti and co-workers.[10] ELPs with 48 positive (K48) or 57 negative (E57) charges 
were produced in E. coli and purified. Protein yields were 1 and 5 mg per liter of 
bacterial cell culture for K48 and E57, respectively. The purity of the products was 
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analyzed by polyacrylamide gel electrophoresis and subsequent staining with either 
SimplyBlueTM SafeStain (Invitrogen) or copper(II) chloride (Figure 1a, left pane). ELPs 
exhibited reduced electrophoretic mobilities compared to globular proteins, a finding 
widely observed with ELPs.[10] It was also observed that the negatively charged variant 
E57 was poorly stained with the SimplyBlueTM SafeStain as well as with Coomassie 
brilliant blue R-250 (data not shown). Staining with copper(II) chloride, however, led 
to a clear E57 protein band and a white K48 protein band against an opaque, whitish-
blue background (Figure 1a, right pane). Mass spectra yielded sharp peaks for all three 
variants (Figure 1b). Determined masses were 24,105 +/- 50 Da for K48 and 28,967 
+/- 50 Da for E57, which is in excellent agreement with the calculated masses of 
24,151 and 28,971 Da, respectively. As expected,[17] K48 and E57 do not exhibit LCST 
behavior until 90°C. Transition of ELPs from the soluble to the insoluble state was 
determined by measuring absorbance at 350 nm (OD350) at temperatures ranging from 
20 to 90°C. No significant increase in the OD350 values for either of the ELP variants 
could be observed at any temperature measured (data not shown). This finding is in 
line with published data, where the incorporation of increasing numbers of lysine 
or glutamic acid residues in ELPs led to an increase in the lower critical solution 
temperature (LCST) at neutral pH values.[7,16] ELPs below their critical solution 
temperature exhibit extensive random coil formation in water.[18,19] To determine the 
secondary structure of K48 and E57, CD spectra were recorded at 20°C. The spectra 
of both polypeptides showed a smaller trough at around 220 nm and a larger trough at 
around 200 nm (Figure 1c). This spectral behavior is usually interpreted to represent 
largely random coil structure with some contribution of α-helical segments.[19,20]
Capsule Preparation and Characterization
After successful expression our next goal was to exploit the high net charges of K48 
and E57 for self-assembly of the ELP variants into supramolecular structures, namely 
multilayer polypeptide capsules, using a Layer-by-Layer (LbL) technique[21] (Figure 
2). This technique is based on the consecutive assembly of oppositely charged 
polymers around a preformed charged spherical template[21] with typical diameter 
from a few hundred nm to a few mm. At the end of the LbL adsorption process, the 
cores can be successfully removed to obtain hollow and intact capsules. Polymer 
containers based on the LbL technique have recently attracted high interest for a 
variety of different applications, ranging from drug delivery systems and targeted 
gene therapy to biosensor devices.[22,23] To date, capsules have been made of synthetic 
and biodegradable polyelectrolytes,[24,25] comprising natural molecules such as 
oligonucleotides[26] and proteins,[27,28] which demonstrates the high versatility of LbL 
assembly.
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Figure 1. Characterization of unfolded, supercharged proteins. a) Purified ELP variants K48 and E57 
examined by SDS-PAGE. Left: 4-12% NuPAGE® gel stained with SimplyBlueTM safe stain (K48: 2 µg, 
E57: 8 µg). Right: 12% SDS-PAGE gel stained with a 0.3 м copper (II) chloride solution (K48: 2 µg, 
E57: 4 µg). b) MALDI-TOF mass spectra of supercharged elastin-like proteins K48 and E57. Left: mass 
spectrum of K48 (m/z is 24,104.6) with internal standard bovine serum albumin (BSA; m/z is 22,135.5 
for BSA +3H and m/z is 33,215.3 for BSA +2H). Right: Mass spectrum of E57 (m/z is 28,967.1) with 
internal standard trypsinogen (m/z is 23,982.0). I = absolute intensity. c) Circular dichroism (CD) 
spectra of aqueous solutions of ELPs K48 (10 µM) and E57 (5µM). Data represent averages of 25 scans.
Figure 2. Schematic illustration of the multiple assembly of the two oppositely supercharged proteins 
onto spherical CaCO3 porous microparticles via LbL assembly technique, and fabrication of a hollow 
protein-based capsule by dissolution of the template core. The turquoise lines represent the supercharged 
negative E57 ELP, the violet lines represent the supercharged positive K48 ELP. For simplicity, only two 
layers are shown. Capsules are not drawn to scale. 
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The main driving force in alternate LBL assembly of multilayer capsules is the 
electrostatic interaction between oppositely charged species. Hence, the number 
of charges per molecule of the two supercharged unfolded proteins K48 and E57, 
employed as component layers of ELP-derived capsules, was calculated and compared 
to the number of charges per molecule of polyelectrolytes (PEs) commonly used for 
capsule synthesis, which served as controls in this work (Table 1). As expected, all 
control PEs have a higher number of charges per molecule than the ELPs except for 
DEXS, which has around 27 charges per molecule. The µmol charges per 1 mg are 
also higher for all control PEs than for the ELPs.






E57 ELP-glutamic acid 28,970 57 1.97
K48 ELP-lysine 24,150 48 1.99
DEXS Dextran sulfate sodium salt from 
Leuconostoc spp.
6,500-10,000 27.79 3.37
pARG Poly-L-arginine hydrochloride 70,000 498 7.11
PSS Poly(sodium 4-styrenesulfonate) 70,000 339 4.84
PAH Poly(allylamine hydrochloride) 56,000 605 10.8
pLL poly-L-lysine hydrobromide 15,000-30,000 108 4.8
Table 1. Calculation of the charges per molecule (ch./mol.) and µmol charges per 1 mg of the 
polyelectrolytes (PE) used in this work.
Using standard LbL preparation techniques[21] and employing supercharged 
proteins E57 and K48 as building blocks, we generated capsules exhibiting the 
following wall structure: (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57, where DEXS 
denotes dextran sulfate and pARG poly(L-arginine), two charged biodegradable 
polymers made from naturally occurring monomers.[24] The use of DEXS/pARG as 
a first bi-layer proved crucial to growing a stable multilayer (E57/K48) wall. In a 
previous experiment, protein capsules assembled by using E57 as first layer showed 
diffusion of the fluorescent layer K48AF488 into the capsule cavity during the LbL steps 
(data not shown). Moreover, after core removal no spherical capsules were detectable 
by fluorescence microscopy, thus confirming that both E57 and K48 were mostly 
localized as complexes inside the CaCO3 cores instead of alternately depositing on the 
template surface (data not shown). It is worth noting that CaCO3 microparticles are high 
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porous with pore diameters ranging from 20 to 60 nm.[29] This allows small molecules 
with a size of several nanometers to penetrate into the template during LbL assembly. 
Thus, in order to prevent diffusion of ELP into the cavities, we decided to assemble 
the ELP multilayer shell after adsorption of one biodegradable bi-layer composed 
of (DEXS/pARG) polymers. As control samples, capsules made of degradable and 
non-degradable polyelectrolytes were fabricated. Degradable capsules, which are 
susceptible to enzymatic degradation, were composed of dextran sulfate (DEXS) as 
the polyanion and of poly(L-arginine) (pARG) as the polycation.[24] Non-degradable 
capsules were made of poly(sodium 4-styrenesulfonate) (PSS) as the polyanion and 
of polyallylamine hydrochloride (PAH) as the polycation. For visualization purposes, 
one layer was fluorescently labeled with Alexa Fluor 488 (AF488; labeling of K48 and 
pARG) or fluorescein isothiocyanate (FITC; labeling of PAH). 
The typical morphologies of core-shell microparticles after LbL assembly with 
the same number of layers but different layer components are presented in Figure 3. 
In the three systems investigated the diameter of the microparticles was found to be 
Figure 3. CLSM images of (a) (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57, (b) (DEXS/
pARG)3(DEXS/pARGAF488)(DEXS/pARG)DEXS and (c) (PSS/PAH)3(PSS/PAHFITC)(PSS/PAH)PSS 
capsules before core removal. The capsule walls were labeled with AF488 (a, b) and FITC (c). Left 
panels: Fluorescence images of green emitting dyes. Central panels: optical transmission images. Right 
panels: corresponding overlay of both fluorescence and transmission channels. The fluorescence signal 
coming from the capsule walls can be seen whereas the spherical shape of CaCO3 porous cores can be 
observed in the corresponding transmission images. Scale bars represent 1 µm.
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in the range of 2-2.5 µm. As shown in the fluorescence channels, the fluorescence 
signal corresponding to the labeled layers, which had been added as tenth layer in the 
ELP capsules and as eighth layer in the biodegradable and non-degradable capsules, 
was detected only in the walls. This indicates that the layers were efficiently adsorbed 
around the spherical templates during the LbL assembly. As expected, the CaCO3 
cores were clearly visible in the corresponding transmission channels. 
After core removal, confocal laser scanning microscopy (CLSM) pictures of the 
resulting capsules were taken (Figure 4). Notably, the dissolution of the core is a 
critical step in the preparation of hollow capsules, as it may result in capsules breaking 
or swelling due to decomposition conditions (i.e., low pH). The fluorescence signal in 
the ELP capsules was found to be still confined to the walls even after core removal, 
showing that the integrity of the multilayer protein shell was not affected during core 
dissolution. In some of the biodegradable (DEXS/pARG) capsules a slight diffusion 
of the labeled polymer pARGAF488 into the cavities was observed, owing to the above 
Figure 4. CLSM images of (a) (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57, (b) (DEXS/
pARG)3(DEXS/pARGAF488)(DEXS/pARG)DEXS and (c) (PSS/PAH)3(PSS/PAHFITC)(PSS/PAH)PSS 
single capsule after core removal. The capsule walls were labeled with AF 488 (a, b) and FITC (c). 
Left column: fluorescence image; middle column: transmission image; right column: overlay. 
The absence of the CaCO3 cores can be clearly observed in the transmission images. Inset: CLSM 
images of several capsules showing spherical and intact capsules after core removal. Scale bars represent 
1 µm.
De Novo Design of Supercharged, Unfolded Protein Polymers
47
mentioned porosity of the CaCO3 cores.
[29] The absence of the cores was clearly 
detected in each capsule sample, as shown in the transmission channels.
The efficient assembly of the protein layers was confirmed by the following control 
experiment: CaCO3 particles were coated with one bi-layer of DEXS/pARGAF488 and 
analyzed by CLSM before and after core removal. Before core removal, the typical 
morphology of capsules enclosed by a fluorescently labeled wall was observed (data 
not shown). After core removal, no capsules were observed in the bulk solution 
indicating that capsules made of only one bi-layer are not stable against the dissolution 
conditions. This result confirms that the protein-based capsules prepared by LbL 
assembly of E57/K48 onto one bi-layer of (DEXS/pARG) were actually composed of 
alternating protein layers with the fluorescently labeled K48AF488 as second-last layer.
Capsules permeability
In order to compare the permeability behavior of protein capsules and control capsules 
based on DEXS/pARG and PSS/PAH layers, dextran with a molecular weight of 
500 kDa and labeled with red fluorescent Alexa Fluor 594, was entrapped inside 
the cavities during synthesis of the CaCO3 cores. After core removal diffusion of 
dextran across the wall of (E57/K48) capsules was observed, whereas no diffusion 
was observed for the control capsules (Figure 5). These data suggest the existence of 
large pores in the wall of supercharged protein-based capsules.
Figure 5. CLSM overlay images of 11-layer (a, d) (E57/K48), (b, e) (DEXS/pARG) and (c, f) (PSS/
PAH) capsules. Capsules are shown before (a-c) and after (d-f) core removal. Capsule cavities were 
loaded with dextran (MW 500 kDa), labeled with red fluorescent AF543. Capsule walls were labeled 
with green fluorescent AF488 (a, b, d, e) or FITC (c, f). After core removal dextran diffused through the 
walls of (E57/K48) capsules, suggesting a higher porosity of the wall compared to the control capsules. 
Scale bars represent 10 µm. 
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Protein capsules were then analyzed by Scanning Electron Microscopy (SEM) and 
Transmission Electron Microscopy (TEM) to gain deeper insight into the structure 
and morphology of the multilayer polypeptide wall, both before and after core 
removal, and to compare their properties to the control capsules. Figure 6 shows the 
SEM images corresponding to the core-shell microparticles previously presented in 
Figure 3. Protein-coated cores and (DEXS/pARG)-coated cores were characterized 
by a thick surface, suggesting dense packing of the polymers in the multilayer shells. 
Figure 6. SEM images of CaCO3 cores after coating (a) (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57, 
(b) (DEXS/pARG)3(DEXS/pARGAF488)(DEXS/pARG)DEXS and (c) (PSS/PAH)3(PSS/PAHFITC)(PSS/
PAH)PSS. The typical spherical, porous-like structure of capsules templated on CaCO3 cores can be 
observed. Scale bars represent 1 µm (top row), 100 nm (bottom row).
In the case of capsules made up of (PSS/PAH) polyelectrolytes, a highly porous surface 
was observed. This might be explained by the adsorption of the polyelectrolytes 
onto the rough surface of the CaCO3 microparticles which results in the formation 
of a porous polyelectrolyte network.[29] After dissolution of the templates, a porous 
network with clear holes was observed in the protein capsules sample (Figure 7), 
whereas in the capsule wall composed of biodegradable PEs no holes were detected. 
Non-degradable capsules exhibited a rather porous wall structure.
In line with the LSM and SEM data the walls of the protein capsules investigated 
under TEM were found to be more porous than biodegradable and non-degradable 
capsules (Figure 8), indicating that the two investigated polypeptides, E57 and K48, 
formed thinner shells during the LbL assembly. Nonetheless we would like to point 
out that the porosity, and thus the permeability, of the protein capsules could be 
reduced by increasing the number of layers employed to grow the multilayer wall or 
by cross-linking the proteins after their adsorption onto the sacrificial core surfaces 
(i.e., by using glutaraldehyde as a cross-linker agent).[27,28] Finally, the use of unfolded, 
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supercharged proteins with a higher number of charges per molecule (see Table 1) 
might be taken into account to build up a multilayer shell with stronger electrostatic 
attractions between each component layer. 
Figure 7. SEM images of (a) (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57, (b) (DEXS/pARG)3(DEXS/
pARGAF488)(DEXS/pARG)DEXS and (c) (PSS/PAH)3(PSS/PAHFITC)(PSS/PAH)PSS capsules after core 
removal. Capsules collapse after core removal indicating the absence of the cores in their cavities. Scale 
bars represent 1 µm (top row), 100 nm (bottom row).
Figure 8. TEM images of (a) (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57, (b) (DEXS/pARG)3(DEXS/
pARGAF488)(DEXS/pARG)DEXS and (c) (PSS/PAH)3(PSS/PAHFITC)(PSS/PAH)PSS capsules after core 
removal. Capsules collapse after core removal indicating the absence of the cores in their cavities.
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Taken together, we successfully assembled multilayers of unfolded, supercharged 
proteins onto a spherical core template. After dissolution of the core the existence of 
capsules with empty interior and stable walls was clearly demonstrated. Compared 
to capsules formed by standard synthetic polyelectrolytes such as poly(styrene 
sulfonate) (PSS) and poly(allylamine hydrochloride) (PAH) the walls of capsules 
based on supercharged proteins were found to be rather porous. This may be due to 
the lower charge density of E57 and K48 compared to PSS and PAH (Table 1), which 
results in a higher mechanical pressure during the dissolution procedure. At any rate, 
the two structural compartments of capsules, cavity and wall, are well defined and 
prove successful and stable assembly. 
Evaluation of In Vitro Cytotoxicity 
Such capsules might be appealing containers for use in biomedicine. Since positively 
charged polymers are the most common source of toxicity in charged systems due 
to their interaction with anionic intracellular components,[30-32] the toxicity of K48 
was investigated and compared to the other positive polyelectrolytes used for the 
synthesis of capsule controls (i.e. PLL, PAH, pARG). A fluorimetric metabolic assay 
employing NIH/3T3 embryonic fibroblast cells was utilized to assess cytotoxicity. 
The normalized fluorescence of Resorufin, a dye indicating metabolically active 
cells, was plotted against polyelectrolyte concentrations (Figure 9). The resulting 
Figure 9. Comparison of the polyelectrolyte-induced toxicity on NIH/3T3 embryonic fibroblasts. Cells 
were incubated with the different polymers in a concentration range from 6.1 x 10-5 mg ml-1 to 1 mg 
ml-1 and some cells were left untreated as positive control for viability. Cell viability was assessed by 
an increase in the fluorescence signal and is given as mean of normalized intensities. The normalized 
fluorescent intensity is plotted against the concentration (c) and shows a sigmoidal concentration-toxicity 
relationship. PLL: poly(L-lysine); PAH: poly(allylamine hydrochloride); pARG: poly(L-arginine). 
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dose response curves yielded the following polymer concentrations causing 50% cell 
death (LD50, mg ml−1) in decreasing order of toxicity: PLL (LD50 = 0.007), PAH 
(LD50 = 0.009), pARG (LD50 = 0.015) and K48 (LD50 = 0.196). PLL, PAH and 
pARG exhibited similar dose response curves with similar LD50 values, whereas 
the curve for K48 was strongly shifted to higher concentration values. This indicates 
that lower concentrations of PLL, PAH and pARG than of K48 are able to induce cell 
death. K48 induces toxicity at the maximum concentration value used (1 mg ml−1) 
and this effect was immediately mitigated by halving the dose. A plateau level of 
viability was reached at a concentration of 3.1 x 10-2 mg ml−1.
CONCLUSION
In this work we demonstrated the expression of supercharged polypeptides consisting 
of repetitive motifs. As a result of incorporating a single charge per almost every 
repeat, unfolded polyelectrolytes were obtained that are perfectly defined regarding 
their number and distribution of charges, monomer composition, stereochemistry and 
dispersity, which is almost impossible by conventional polymerization techniques. 
With K48 for example, 1 positive charge per 5.7 amino acids was reached. ELPs 
with charged amino acids as guest residues have already been produced, but with 
much lower charge densities than reported herein.[16] So far only a single folded 
protein, Green Fluorescent Protein (GFP), was equipped with similar amounts 
and densities of charges.[33] However, within GFP the charges were by far not as 
equally distributed as in the ELP backbone. In this respect we demonstrated that the 
concept of supercharging by genetic engineering can be extended to other peptide-
based biopolymers. When comparing supercharged ELPs with naturally occurring 
polypeptides, we see that with K48 it was even possible to realize a charge density 
comparable to only a few naturally occurring unfolded proteins,[33,34] all while using 
a minimal set of the amino acid alphabet. 
It was further shown that the high number of charges of these de novo designed 
proteins could be exploited for the fabrication of supramolecular structures. 
Oppositely charged variants were transformed into multilayer capsules by electrostatic 
interactions employing the widely used Layer-by-Layer technique. Due to their low 
toxicity, supercharged proteins like the highly charged ELPs presented in this work 
promise to be a favorable alternative to their chemically synthesized counterparts in 
the context of biomedical scaffolds. In the future we will employ supercharged ELPs 
for the generation of other electrostatically induced polymeric architectures such as 





E.coli XL1-Blue competent cells were purchased from Stratagene (La Jolla, CA). 
The pUC19 cloning vector, restriction endonucleases, T4 DNA ligase (LC), Fast 
APTM thermosensitive alkaline phosphatase (Fast AP), and GeneJETTM Plasmid 
Miniprep kit were purchased from Fermentas (St. Leon-Rot, Germany). Digested 
DNA fragments were purified using QIAquick® spin miniprep kits from QIAGEN, 
Inc. (Valencia, CA). The pET-25b(+) vector and E.coli BLR(DE3) competent 
cells were purchased from Novagen Inc. (Milwaukee, WI). Oligonucleotides were 
synthesized by biomers.net (Ulm, Germany). BactoTM tryptone and BBLTM yeast 
extract were purchased from Becton, Dickinson and Co. (Sparks, MD). Potassium 
phosphate monobasic, potassium phosphate dibasic, sodium phosphate monobasic, 
sodium phosphate dibasic, sodium chloride, and glycerol were purchased from Merck 
KGaA (Darmstadt, Germany). Ampicillin and imidazole were purchased from Roth 
(Karlsruhe, Germany). Isopropyl ß-thiogalactopyranoside (IPTG) was purchased 
from Duchefa (Harlem, Netherlands). 3,5 dimethoxy-4-hydroxycinnamic acid and 
internal standards bovine serum albumin and trypsinogen were purchased from 
LaserBio Labs (Sophia-Antipolis, France). Poly(sodium 4-styrenesulfonate) (PSS, 
Mw ~70,000), poly(allylamine hydrochloride) (PAH, Mw ~56,000), poly(fluorescein 
isothiocyanate allylamine hydrochloride) (PAHFITC, Mw ~56,000), poly-L-arginine 
(pARG, Mw> 70 kDa), dextran sulfate (DEXS, Mw ~10 kDa), poly-L-lysine 
hydrobromide (pLL, Mw 15,000 – 30,000 Da), calcium chloride dehydrate (CaCl2), 
Sodium carbonate (Na2CO3) and ethylenediaminetetraacetic acid (EDTA) were 
purchased from Sigma-Aldrich. Alexa Fluor488, Alexa Fluor 594 carboxylic acid 
succinimidyl ester and amino dextran (Mw ~500,000) carboxylic acid succinimidyl 
ester were obtained from Molecular Probes (Invitrogen). All chemicals were used as 
received. Ultrapure water with a resistivity greater than 18.2 MW cm was used for 
all experiments.
Monomer gene synthesis and gene oligomerization
Construction of the monomer genes and subsequent multimerization were performed 
as described by Chilkoti and co-workers.[10] Briefly, a monomer gene was constructed 
from eight 5’-phosphorylated, PAGE-purified synthetic DNA oligonucleotides. For 
annealing, equimolar mixtures of the oligonucleotides in T4 DNA ligase buffer were 
heated to 94°C and then slowly cooled down to 4°C, yielding a double-stranded DNA 
cassette with EcoRI and HinDIII compatible ends. PUC19 was digested with EcoRI 
and HinDIII, dephosphorylated with Fast AP and run on a 1% agarose gel in TAE 
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buffer (per 1L, 108 g Tris base, 57.1 ml glacial acetic acid, 0.05 M EDTA, pH 8.0). 
The vector band was cut out and purified using a spin column purification kit. The 
annealed oligonucleotides were ligated to the linearized vector. For transformation, 
200 µL of chemically competent E.coli XL1-Blue cells were combined with 5 µL 
of the ligation mixture and further treated according to the manufacturer’s protocol. 
Cells were spread on Lysogeni broth (LB) agar plates (for 1L, 10 g BactoTM tryptone, 5 
g BBLTM yeast extract, 5 g NaCl, 15 g agar) supplemented with 100 µg/ml ampicillin, 
and incubated overnight at 37°C. Colonies were picked and grown in 6 ml LB media 
(for 1L, 10 g BactoTM tryptone, 5 g BBLTM yeast extract, 5 g NaCl) supplemented 
with 100 µg/ml ampicillin overnight, and plasmids were isolated using the GeneJET 
Plasmid Miniprep kit. Positive clones were verified by plasmid digestion with EcoRI 
and HinDIII and subsequent gel electrophoresis. The DNA sequence of putative inserts 
was further verified by DNA sequencing (SequenceXS, Leiden, The Netherlands). 
Gene oligomerization was performed as described by Chilkoti and co-workers.
[10] Positive clones were verified by plasmid digestion with EcoRI and HinDIII 
and subsequent gel electrophoresis. The DNA sequences of putative inserts were 
further verified by DNA sequencing (SequenceXS, Leiden, The Netherlands). 
The resulting ELP gene sequences encoded for the positively charged ELP 
sequences [(VPGKG)12(VPGVG)]4, hereafter K48, and [(VPGEG)10(VPGVG)
(VPGEG)11(VPGVG)]3, hereafter E57, with V denoting valine, P proline, G glycine, 
K lysine, and E glutamic acid. As the recognition sites of the restriction enzymes 
PflMI and BglI had to be preserved, a valine residue instead of a lysine or glutamic 
acid residue was incorporated with every step of oligomerization.
Expression vector construction
The expression vector pET 25b(+) (Novagen) was modified by cassette mutagenesis 
as described by Chilkoti and co-workers.[10] The DNA sequence spanning NdeI to 
EcoRI was exchanged for a sequence which incorporates a unique Sfi I recognition site 
and which encodes for an affinity tag consisting of six histidine residues (Figure 10). 
Figure 10. Sequence inserted into pET-25b(+) between recognition sites NdeI and EcoRI. The modified 
pET-25b(+)-SfiI-H6 vector contains a unique SfiI recognition site to insert ELP genes into the vector, and 




The modified pET 25b(+) expression vector was digested with SfiI, dephosphorylated 
and purified using a microcentrifuge spin column kit. The respective ELP gene was 
excised from the pUC19 vector by digestion with PflMI and BglI, and the excised gene 
was purified by agarose gel extraction following gel electrophoresis. The linearized 
vector and ELP-encoding gene were ligated, transformed into XL1-Blue cells, and 
screened as described above. 
Protein expression and purification
E.coli BLR (DE3) cells (Novagen) were transformed with the pET expression vectors 
containing the respective ELP genes. For protein production, Terrific Broth medium 
(for 1L, 12 g tryptone and 24 g yeast extract) enriched with phosphate buffer (for 1L, 
2.31 g potassium phosphate monobasic and 12.54 g potassium phosphate dibasic) 
and glycerol (4 ml per 1L TB), and supplemented with 100 µg/ml ampicillin was 
inoculated with an overnight starter culture to an initial OD600 of 0.1 and incubated 
at 37°C with orbital agitation at 250 rpm until OD600 reached 0.7. Protein production 
was induced by addition of IPTG to a final concentration of 1 mM. Cultures were then 
continued for an additional 4 h post-induction. Cells were subsequently harvested by 
centrifugation (7,000 x g, 20 min, 4°C), resuspended in lysis buffer (50 mM sodium 
phosphate buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole) to an OD600 of 100 and 
disrupted with a French Press. Cell debris was removed by centrifugation (40,000 x 
g, 90 min, 4°C). Proteins were purified from the supernatant under native conditions 
by Ni-sepharose chromatography (GE Healthcare). Product-containing fractions 
were pooled and dialyzed against Ultrapure water (>18 MΩ). K48 was further 
purified by affinity chormatography using a Heparin HP column (GE Healthcare) 
and protein-containing fractions were dialyzed against Ultrapure water (>18 MΩ). 
Purified proteins were stored at -20°C or lyophilized and stored at room temperature 
until further use.
Protein characterization
The concentrations of the purified ELPs were determined by measuring absorbance at 
280 nm using a spectrophotometer (NanoDropTM, Thermo Scientific). Protein purity 
was analyzed by PAGE (poly(acrylamide) gel electrophoresis) on a 4-12% NuPAGE® 
Bis-Tris gel (Invitrogen) and subsequent staining of the gel with SimplyBlueTM 
SafeStain (Invitrogen). Furthermore, purified proteins were characterized by SDS-
PAGE (SDS - sodium dodecyl sulfate) on a 12% polyacrylamide gel according to 
Laemmli[35] and subsequent copper (II) chloride staining as reported by Lee and 
coworkers.[36] Mass spectrometric analysis was performed using a 4800 Plus MALDI-
TOF/TOF Analyzer (Applied Biosystems, Foster City, CA, USA). The samples were 
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prepared in a recrystallized 3,5 dimethoxy-4-hydroxycinnamic acid matrix with the 
calibration standards bovine serum albumin (MW = 66,429.9) for K48 and trypsinogen 
(MW = 23980.9) for E57. Mass spectra were recorded in positive ion mode with the 
4000 Series Explorer Software, version 3.0 (Applied Biosystems, Foster City, CA, 
USA). The data were analyzed in Data Explorer, version 4.9 (Applied Biosystems, 
Foster City, CA, USA). 
Analysis of secondary structure
Circular dichroism (CD) spectra were recorded using a Jasco-815 spectropolarimeter 
(Jasco, Japan). Measurements were carried out at room temperature with a cell path 
length of 1 mm. The polypeptide concentrations in ultrapure water were 10 and 5 µM 
for K48 and E57, respectively. 
LCST behavior analysis
To characterize the ELP inverse temperature transition, the OD350 of K48 and E57 ELPs 
in ultrapure water at a concentration of 57 and 24 µM, respectively, were measured as 
a function of temperature on a Jasco V630 spectrophotometer. Measurements were 
performed between 20 and 90°C by increasing the temperature every 10 min in 5°C 
increments. 
Labelling of proteins
Alexa Fluor® 488 sulfodichlorophenol ester (AF488) was purchased from Molecular 
Probes (Invitrogen) and dissolved in DMF to a concentration of 10 mg/ml. To 3.15 
mg of K48 in 0.1 M sodium carbonate buffer, pH 8.6, an equimolar amount of AF488 
was added under vigorous stirring. After incubation for 2 h at room temperature 
under vigorous stirring, hydroxylamine solution (pH 8.6) was added to a final 
concentration of 0.14 M and incubated for additional 90 min at room temperature. 
Uncoupled dye was removed by size exclusion using an illustra NAP™-25 column 
(GE Healthcare) and 0.1 M sodium carbonate buffer (pH 8.6) as equilibration and 
elution buffer. Protein-containing fractions were pooled and dialyzed (cut-off 500 
Da) against Ultrapure water (>18 MΩ). Protein concentration was determined using 
the following equation:
c [mg/ml] = (A280 – 0.11 * A495) * MWK48                 (1)
where A280 and A495 are the absorbance values at 280 and 495 nm, respectively, and 
MWK48 is the molecular weight of K48. The labeled protein (K48AF488) was lyophilized 
and stored at room temperature until further use.
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Cytotoxicity assay of positively charged polyelectrolytes (PEs)
NIH/3T3 embryonic fibroblasts were seeded in a 96-well-platte (Greiner by Sigma-
Aldrich) at a cell density of 104 cells/well in 100 µL growth medium (DMEM-F12 
Ham´s basal medium supplemented with 10% calf serum, 1% L-glutamine and 1% 
penicillin/streptomycin whereby all material were provided by Sigma-Aldrich). 
The next day, the cells were incubated with the PEs under investigation (i.e. PLL, 
PAH, pARG, and K48) for 24h. A starting concentration of 1 mg/ml was used for 
each PE and consecutively halved until a final concentration of 6.1 x 10-5 mg/ml. All 
concentrations were done in duplicate. Cells that were not treated with any PE served 
as a positive control for viability. After 24 h, the cells were washed once with PBS, 100 
µL of a 10% Resazurin (TOX-8 kit from Sigma-Aldrich) solution (in growth medium) 
were added to each well and incubated for 3 h at 37°C and 5% CO2. Resazurin is a 
blue, non-fluorescent sodium salt, which is converted to resorufin by metabolically 
active cells. Resorufin is a pink, fluorescent sodium salt that accumulates outside 
the cells. This reduction process requires functional mitochondrial activity which is 
inactivated immediately after cell death. Fluorescence spectra were measured using 
a 96-microwell plate reader connected to a Fluorolog® spectrofluorometer (Jovin 
Yvon) at an excitation wavelength of 560 nm. The emission was recorded in the 
range of 572-650 nm with 1 nm resolution and a slit of 5 nm. Firstly, the mean 
of the intensities of the emission spectra of the duplicates was calculated and then, 
the maximum intensity values found in the range 578-585 nm were also averaged. 
The mean background signal (640-650 nm) was subtracted from the mean maximum 
emission values and subsequently normalized with the maximum fluorescence value 
obtained. The maximum fluorescence value corresponded not always to the untreated 
cells, probably due to the formation of hydroresorufin, a transparent nonfluorescent 
product which is formed upon further reduction of resorufin by viable cells.[37] The 
experiments were repeated three times for each PE. The means of the normalized 
fluorescence intensity values of the three experiments (I/Imax) were plotted against 
the different concentrations of the PEs. A sigmoidal distribution was obtained and 
fitted as a function of a logistic dose response curve which enables us calculating the 
PE concentration yielding 50% cell death (LD50). 
Preparation of CaCO3 microparticles 
For each capsule system, CaCO3 microparticles were precipitated from solutions 
of calcium chloride and sodium carbonate under vigorous stirring.[29] Briefly, equal 
volumes (0.615 ml) of aqueous CaCl2 and Na2CO3 solutions (0.33 M) were mixed 
in the presence of 5 mg/ml 500 kDa dextran and thoroughly agitated on a magnetic 
stirrer for 30 s at room temperature. After the agitation, the mixture was left without 
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stirring for 4 min at room temperature. During this time precipitation of CaCO3 
occurs and spherical CaCO3 particles with an average diameter ranging from 2.5-3.5 
µm are formed. Dextran is integrated in the cores.[38] Subsequently, the precipitate 
was separated from the supernatant by centrifugation (6000x g, 6 s) and washed three 
times with pure water to remove unreacted species. In the last step, the particles were 
washed with acetone and air-dried. We incorporated dextran in the CaCO3 cores, as 
dissolution of the cores including dextran by addition of EDTA was faster than that of 
cores without dextran. Naturally, in this way dextran remains in the capsule cavities 
after core dissolution. The whole powder obtained from one synthesis (about 20 mg) 
was employed for the LbL coating.
Fabrication of multilayer capsules
The resulting spherical cores were coated by sequential incubation of the particles 
in the corresponding polyanion and polycation solutions. Three different types of 
microcapsules made of different layer constituents were prepared by sequential 
adsorption of negatively charged and positively charged species on CaCO3 
microparticles (~20 mg per samples) to give the following shell architectures 
comprising 11 layers in total:
PSS/PAH - capsules: (PSS/PAH)3(PSS/PAHFITC)(PSS/PAH)PSS,
DEXS/pARG - capsules: (DEXS/pARG)3(DEXS/pARGAF488)(DEXS/pARG)DEXS, 
and E57/K48 - capsules: (DEXS/pARG)(E57/K48)3(E57/K48AF488)E57. 
The adsorption of polyelectrolytes PSS, PAH, PAHFITC and DEXS was conducted in 2 
mg/ml solutions in 0.5 M NaCl, whereas the polyelectrolyte pARG and the positively 
charged and negatively charged proteins (K48 and E57, respectively) were suspended 
in 1 mg/ml solutions in 0.5 M NaCl. The pH of the polyelectrolyte solutions was 
adjusted to 6.5 by addition of NaOH, whereas the pH of the protein solutions was 
maintained neutral (~7.2-7.6). The adsorbing protocol started with the negatively 
charged polymer (PSS or DEXS). PAHFITC (obtained from Sigma) and PAHAF488 
(obtained by reacting NHS-ester modified Alexa488 to the amino groups of PAH 
or pARG) were used instead of non-labeled polycation for the eighth layer of the 
multilayer polymer shell, so that the capsules had a green emitting dye label in their 
walls. Similarly, K48AF488 was used for the tenth layer of the protein capsules to label 
the capsule walls. After addition of each charged species, samples were continuously 
shaken for 12 min. The coated particles were then centrifuged at 6000x g for 6 s 
and the supernatant containing unabsorbed species was removed. This procedure 
was repeated three times after each absorption step. After each cycle the CaCO3 
suspension was resuspended with ultrasound pulses to prevent aggregation. At the 
end eleven layers were deposited for each capsule type, starting from the polyanion. 
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We want to point out that in the case of the protein capsules the first two layers were 
DEXS and pARG in order to mechanically stabilize the capsules. As the capsule 
cavities include dextran, the first layer of dextran sulfate has the same constituency as 
the interior of the capsule cavity. Poly-L-arginine is a polypeptide and thus similar in 
nature to the following layers of supercharged proteins. After assembly of the capsule 
walls by LbL deposition the CaCO3 core was removed by complexation with EDTA. 
Coated CaCO3 particles were shaken for 2 min with 1 ml of an EDTA solution (0.2 M, 
pH 5), followed by centrifugation and redispersion in 1 ml of a fresh EDTA solution 
(0.2 M, pH 7). The thus obtained hollow microcapsules with some dextran in their 
cavities were washed five times with pure water with centrifugation at 1000 x g for 8 
min. The microcapsules were finally stored as suspension in water at 4°C. 
Capsule characterization
Confocal laser scanning microscopy (CLSM)
Fluorescent images were taken by a confocal microscope (LSM 510 META, Zeiss). 
The excitation wavelength was 488 nm. Samples were observed through a 100X/1.45 
NA oil-immersion PLAN-FLUOAR objective. Capsules labeled with FITC and 
Alexa488 fluorescence were studied with the Ar/Kr laser 488 nm. A 20 μL drop 
sample was placed onto a cover glass and imaged in liquid.
Electron Microscopy 
Protein capsules were analyzed by Scanning Electron Microscopy (SEM) and 
Transmission Electron Microscopy (TEM). SEM micrographs were recorded on a 
JEOL JSM-7500F SEM at an operation voltage of 2.00 kV. A 10 μl drop sample was 
placed onto a cover glass, dried at room temperature, and sputtered with a platinum 
layer under vacuum for 90 s. TEM micrographs were recorded on a JEOL 3010 TEM 
operating at an accelerating voltage of 300 kV. A 10 μl drop sample was placed on a 
Formvar®/carbon coated TEM-grid (300 Mesh 3.05 mm Copper, Plano GmbH) and 
dried at room temperature before imaging.
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Insufficient biolubrication is an increasingly acute medical problem around the world.
[1-3] It may impede proper speech, mastication and swallowing, underlie excessive 
friction and wear of articulating cartilage surfaces in hips and knees, cause vaginal 
dryness and result in dry, irritated eyes. Treatment with current biomimetic lubricants 
is inadequate for properly restoring the biolubrication necessary for growing number 
of patients. Here, we introduce a new strategy to address this need using non-toxic 
and biocompatible recombinant supercharged, unfolded proteins (SUPs) containing 
36 (K36) or 72 (K72) positive charges and based on elastin-like polypeptides. These 
materials rejuvenate lubrication through naturally occurring salivary conditioning 
films (SCFs), a mechanism explained using surface analytical techniques. Adsorbed 
K36 and K72 bind with glycosylated mucins in SCFs through electrostatic 
interactions and induce rigidity in the film to a degree that correlates with the amount 
of positive charge. The extra charges in the case of K72 present residual cations in 
the SCFs that await further electrostatic interactions. Upon renewed exposure to 
saliva the K72 cations recruit negatively charged glycosylated mucins from saliva 
to create a soft, hydrated film. Such SCFs are marked by structural rigidity, long-
range repulsive forces and a higher degree of glycosylation, which together result in 
effective biolubrication. Furthermore, we identify a friction force signature for the 
SCFs containing K72 unique among other lubricants, indicating particularly high 
inherent structural stability for lasting lubrication. Thus cationic SUPs represent a 
minimally interfering, novel therapeutic modality to improve biolubrication when 
availability of naturally occurring proteins is reduced. 
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Biolubrication is an essential feature of health and can become impaired in the elderly 
or diseased. Sjögren’s syndrome,[4] for instance, is a disease causing a variety of 
symptoms like dry eyes,[2] dry mouth,[3] vaginal dryness[5] and excessive friction and 
wear at the knee and hip joints.[6] Biolubrication is mediated by glandular secretions 
containing (glyco-)proteins that adsorb at the sliding interface and  form a so-called 
conditioning film. Although water forms the basis of all biolubrication phenomena, 
it is easily removed from in between sliding surfaces during physiological activities 
associated with high contact pressures. To counter this, conditioning films providing 
biolubrication contain different glycoproteins that retain water molecules to generate 
repulsive hydration forces at the interface of the sliding surfaces.[7,8] Oral lubrication 
by adsorbed salivary conditioning films (SCFs) is essential to facilitate speaking and 
mastication and protects against wear due to erosion and abrasion.[7,9,10] Maintenance 
of adequate biolubrication in the oral cavity is not only challenged by disease and 
aging, but also by high contact pressures. Contact pressures on molar surfaces during 
mastication can be as high as 86 MPa which is one order of magnitude higher than 
the pressures experienced in hip and knee joints.[8,11] This load makes the maintenance 
and restoration of lubrication more challenging in the oral cavity than in other parts 
of the human body where articulating surfaces are involved. 
Often, oral dryness is due to insufficient retention of water molecules in adsorbed 
SCFs due to low salivary flow rates (< 1 ml min-1) or dysfunction of a particular 
salivary gland.[12] Patients suffering from oral dryness symptoms are treated with 
artificial salivas, often containing lubricants like pig gastric mucins, polyacrylic acid 
and carboxymethyl cellulose.[13] However, artificial salivas only yield temporary 
relief in patients, as the adsorbed conditioning films are unable to sufficiently retain 
water due to lack of structural integrity. 
Intrigued by the facts that cationic polyelectrolytes are able to improve the 
mechanical strength of polysaccharide multilayers[14] and can form polymer-brush 
like structures,[15] we tested their ability to act as additive to improve oral lubrication. 
Among the existing polyelectrolytes, recombinant supercharged unfolded proteins 
(SUPs) derived from elastin-like polypeptides (ELPs) constitute an attractive group 
of proteins that may assist in restoring biolubrication. Not only can cationic SUPs 
interact with the negatively charged, naturally occurring mucins, they also possess 
significantly lower cytotoxicity than other cationic polyelectrolytes commonly used 
in biomedical applications.[16] Moreover, they are well-defined with respect to their 
length, composition and charge density and are broken down into non-toxic, naturally 
occurring amino acids upon digestion. However, the potential of SUPs to improve 
biolubrication and mechanical strength of naturally occurring conditioning films has 
to be investigated.  
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The aim of this study is to evaluate the role of SUPs with 36 (K36) and 72 
(K72) positive charges in modifying the lubrication of adsorbed SCFs. A quartz 
crystal microbalance with dissipation monitoring (QCM-D) was used to examine 
changes in SCF structure after K36 and K72 adsorption and renewed exposure to 
saliva. Colloidal probe atomic force microscopy (AFM) was applied to determine 
friction and repulsive force characteristics and topography of the SCFs. Finally, 
X-ray photoelectron spectroscopy (XPS) was used to determine their degree of 
glycosylation. 
RESULTS
Cationic SUPs based on ELPs consist of repeats of five amino acids, containing the 
aliphatic residues glycine (G), valine (V), proline (P), and positively charged lysine 
(K). The gene sequence of the SUP monomer gene SUP K9, which encodes for the 
polypeptide sequence [(GVGVP)(GKGVP)9], and oligomerization of the gene are 
described in the supplementary information (supplementary Figures S1 and S2). 
After oligomerization, SUP genes encoding for [(GVGVP)(GKGVP)9]4 (K36) and 
[(GVGVP)(GKGVP)9]8 (K72) were cloned into a modified bacterial expression 
vector, pET25b(+)-SfiIHis6, and successfully expressed in E. coli. SUPs were purified 
from the crude cell extract by affinity and ion exchange chromatography. Protein 
integrity and purity were confirmed by gel electrophoresis and mass spectrometry 
(supplementary Figure S3). Typical yields were 45 mg (K36) and 40 mg (K72) of 
purified recombinant protein per liter of culture. 
The formation of SCFs on gold (Au) coated quartz crystals and the effects of their 
exposure to recombinant K36 and K72 or buffer, followed by renewed adsorption 
of salivary proteins, were observed real-time in the QCM-D, as presented in Figure 
1a-c. Exposure of an existing SCF to buffer (Figure 1a) yielded a small change in the 
oscillating sensor frequency (Δf3) and dissipation (ΔD3), whereas exposure to K36 
(Figure 1b) and K72 (Figure 1c) solutions caused significant decreases in Δf3 and ΔD3 
that were largest for K72. Subsequent removal of the protein solution by perfusing 
the QCM-D chamber with buffer indicated a structural decrease in the softness of the 
SCFs, expressed as the ratio (ΔD3/Δf3). Again, this effect was larger after exposure 
to K72 solution than after exposure to K36 solution (Figure 1d). Renewed salivary 
exposure over the SCFs was initiated immediately after treatment with buffer or 
recombinant protein solutions (Figure 1a-c) because such experimental conditions 
reflect best the in vivo situation of immediate reflow of saliva in the oral cavity. 
Renewed perfusion of the QCM-D chamber with saliva did not affect the structural 
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softness of the SCF exposed to buffer (Figure 1d), but salivary films formed on SCFs 
exposed to K36 solution became softer again to a level comparable to buffer exposed 
SCFs. The SCFs formed on films with adsorbed K72, however, were significantly 
(p < 0.05, two tailed Student t-test) softer than SCFs formed after exposure to 
buffer or adsorption of K36. Bare Au coated QCM crystals have a smooth surface 
(supplementary Figure S4a), presenting uneven, globular structures upon adsorption 
of salivary proteins (supplementary Figure S4b) with maximal heights of around 22 
nm. Similar structures are observed when adsorbed K36 or K72 are part of the SCF, 
but their heights differ considerably from 16 nm for films comprising K36 to 32 nm 
when K72 is involved (supplementary Figure S4c, d).
Figure 1. Influence of adsorption of recombinant cationic proteins and renewed exposure 
to saliva on the softness of salivary conditioning films. (a, b, c) Examples of the QCM-D 
response as a function of time to protein adsorption from saliva on Au coated quartz crystal 
surfaces, subsequent adsorption to cationic recombinant proteins (2 min) and renewed 
exposure to salivary proteins, expressed as changes in third harmonic frequency (∆f3, thick 
line) and dissipation (∆D3, thin line), together with structural softness of the adsorbed films. 
(a) buffer/ no recombinant protein adsorption; (b) adsorption of recombinant K36 and; (c) 
adsorption of recombinant K72. (d) Structural softness of salivary conditioning films after 
with and without (“buffer”) adsorbed recombinant cationic proteins and renewed exposure 
to saliva. Error bars represent the standard deviation over five independent measurements. 
Statistically significant (p < 0.05, two tailed Student t-test) differences in softness of films 
with adsorbed K36 or K72 with respect to control films are indicated by *. Differences in 
softness between films with adsorbed K72 and K36 are indicated by #. 
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In a next step, the lubrication properties of the SUP-modified films were investigated 
by colloid probe AFM. Friction forces on bare Au-coated crystals increased linearly 
(R2 = 0.95) with normal force up to 35 nN, corresponding to a coefficient of friction 
(COF) of 0.28 (Figure 2a). Upon adsorption of a SCF, friction forces appeared almost 
two times lower than on Au coated crystals with a COF of 0.19, and linearity broke 
down at normal forces above 14 nN. Note that the negative friction forces at a normal 
force of 1.5 nN represent the known limitation of AFM to measure very low friction 
forces.[17] However, measurements on SCF after recombinant protein adsorption and 
subsequent exposure to saliva clearly showed still lower friction forces (Figure 2b). 
Linearity corresponding with a COF of 0.08 persisted up to a normal force of 20 
nN for K36, while linearity (R2 = 0.94) corresponding to an extremely low COF of 
0.06 existed over the entire range of normal forces applied for K72-modified films, 
indicative of a high structural integrity. Contact of the AFM colloidal probe with the 
Au-coated quartz crystal (Figure 2c) shows a hard material compared with the softer 
SCFs due to long-range repulsive forces between SCFs and the approaching colloidal 
probe. The repulsive force range arising from the SCFs increased with the number of 
positive charges after adsorption of recombinant cationic SUPs (Figure 2c). To gain 
more insight into the structural composition of the modified SCFs, XPS was applied 
to measure the degree of glycosylation, which is related to the water content of the 
surface (see Figure 2d and supplementary Table S1). Glycosylation in the SCFs with 
no adsorbed SUPs amounts to 5.8 ± 0.8 % and increases with the molecular weight 
of the adsorbed SUPs to 6.9 ± 0.3% and 7.2 ± 0.6 % in SCFs with K36 and K72, 
respectively. 
DISCUSSION
From the measurements described above one can conclude that cationic recombinant 
SUPs adsorb on SCFs and decrease their structural softness, i.e. increase their rigidity. 
SUPs carrying more positive charges create more rigid films, and more efficiently 
recruit salivary proteins to form a SCF with thicker globular structure and higher 
degree of glycosylation, generating a longer repulsive force range and more stable, 
low friction.
Patients with oral dryness symptoms have reduced salivary flow rates, but naturally 
occurring salivary proteins are always present. This study is the first in which naturally 
occurring salivary proteins are recruited through the adsorption of recombinant, 
cationic proteins to improve several parameters crucial for effective biolubrication. 
Our approach represents a groundbreaking strategy for artificial biolubrication, where 
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additives act in concert with and enhance the natural lubricants rather than simply 
replacing them. A proof of principle was obtained for oral lubrication, the most 
Figure 2. Influence of adsorption of recombinant cationic proteins and renewed exposure to saliva 
on the friction forces, repulsive force upon approach and glycosylation of salivary conditioning films. 
(a, b) Friction force as a function of normal force during increasing (closed symbols) and decreasing 
(open symbols) normal forces. (a) bare Au coated QCM crystal  and SCF without adsorbed recombinant 
cationic proteins; (b) SCFs with adsorbed recombinant cationic proteins K36 or K72 and after renewed 
exposure to salivary proteins. Error bars on all the friction forces represent standard deviation over 12 
measurements. (c) Example of the repulsive force as a function of tip separation distance for bare Au 
coated QCM crystals, SCF without adsorbed recombinant cationic proteins and with adsorbed K36 
or K72. The repulsive force range (D) for all adsorbed protein films is calculated with respect to hard 
contact recorded on bare Au coated crystal surface (inset of Fig. 2c). Error bars represent the standard 
deviations over 30 force curves. (d) The degree of glycosylation (%Oglyco) for SCFs without adsorbed 
recombinant cationic proteins and with adsorbed K72 or K36, obtained from a decomposition of the O1s 
photoelectron peak in XPS. Error bars represent the standard deviations over three independent XPS 
measurements on differently prepared samples. Statistically significant (p < 0.05, two tailed Student 
t-test) differences in repulsive force range (c) and glycosylation (d) of SCF with K36 or K72 with 
respect to SCF in absence of adsorbed recombinant proteins are indicated by *signs. Differences in 
repulsive force range between SCF with adsorbed K36 or K72 are indicated by #sign.
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challenging environment for biolubrication, but similar recruitment mechanisms may 
be applied in other parts of the human body as well.
SCF is composed of glycosylated, high-molecular weight mucins that adsorb in 
loops and trains and thereby provide a scaffold to hold and retain water molecules 
at the surface, while adsorbed smaller proteins like proline-rich proteins, histatins, 
lysozymes, and amylases may be found underneath the loops and between the trains 
(Figure 3a).[18] Based on the measurements presented above, we suggest a model 
for the interaction of cationic SUPs with an existing SCF and for how the adsorbed 
cationic proteins may be further involved in the recruitment of salivary proteins 
during renewed exposure of saliva. K36 and K72 bind to the negatively charged 
mucins leading to elimination of electrostatic stabilization of the adsorbed film and 
its subsequent collapse, forming a rigid structure (Figure 3b). K72 is a polypeptide 
consisting of more than 400 amino acids with 72 positively charged groups evenly 
distributed along the polymer backbone. The higher number of positive charges in K72 
compared with K36 neutralizes more negative charges in the SCF and positive charges 
of adsorbed K72 remain available for further interactions with negative charges. This 
can be concluded from zeta potential measurements (supplementary Figure S5), 
showing more positive charges on SCFs exposed to K72 than on K36-treated and 
untreated SCFs. Thus, uncompensated positive surface charges of adsorbed K72 on a 
SCF can trigger further recruitment of negatively charged glycosylated mucins during 
renewed exposure to saliva (Fig. 3b; right panel), resulting in a softer highly hydrated 
over-layer (Figure 3c). This recruitment process rejuvenates the film, as it can bind 
to more water molecules. This is one critical step beyond simply restoring the film 
structure, as observed in SCFs formed after reflow of saliva over K36-treated and 
buffer-treated SCFs. Note that an analogous layer-by-layer assembly of bovine mucins 
using chitosan as a cationic polyelectrolyte has been demonstrated previously.[19] 
The rigid and hydrated SCF, modified with adsorbed K72 and after renewed 
exposure to saliva, shows low friction forces and a structural integrity that is not 
compromised at higher contact pressures, in contrast to films containing K36 or 
untreated films. The breakdown of structural integrity in these latter films can be seen 
from a discontinuity in the linearity of friction force against the normal force.[20,21] In 
order to determine the mechanical strength of the SCFs, we have applied Von Mises 
distortion energy criterion that relates the normal force at which the discontinuity 
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where, Rtip is the radius of the colloidal tip (2.25 µm), δ is the elastic displacement 
of the film determined from a Hertzian fit to the force-distance curves as obtained by 
colloidal probe AFM and ff  is the friction force at fL. Accordingly, yield strength for 
SCF in absence of recombinant cationic SUPs is 80 ± 12 kPa, increasing to 102 ± 8 
Figure 3. Architecture of salivary conditioning films after adsorption of recombinant cationic 
proteins with different numbers of positive charges and renewed exposure to saliva. (a) 
Adsorbed salivary conditioning film, showing glycosylated mucins adsorbed in loops and 
trains over a layer of adsorbed densely packed low-molecular weight proteins, including 
proline-rich proteins, histatins and lysozymes. (b) Salivary conditioning films after adsorption 
of K36 (left panel) and K72 (right panel). Recombinant cationic proteins interact with the 
negatively charged glycosylated mucins, causing collapse of the glycosylated structure 
through electrostatic interaction. In case of K72, not all positive charges engaged with the 
mucins and remain available for further interaction (right panel). (c) Salivary conditioning 
films with adsorbed cationic proteins and after renewed exposure to saliva. No mucins are 
recruited in the presence of adsorbed K36 (left panel), but remaining positive charges in the 
film possessing adsorbed K72 recruit mainly glycosylated mucins to form a soft mucinous 
layer over a compact SCF (right panel). 
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kPa in the presence of adsorbed K36. In contrast, no discontinuity in the linearity of 
friction force against the normal force was observed for K72-treated films within the 
range of normal forces applied, indicating that the yield strength of SCFs in presence 
of K72 exceeds 102 kPa. 
An ideal biolubricant-like artificial saliva should lubricate the oral surfaces and at 
the same time sustain this lubrication for lasting benefits. Here we demonstrate that 
non-toxic, recombinant cationic SUPs adsorb on SCFs to recruit further glycosylated 
mucins from saliva, provided the number of positive charges is sufficiently high. These 
hydrated and rigid films improve interfacial lubrication and maintain their structural 
integrity upon high contact pressures. Current generations of artificial salivas are 
inadequate to restore oral lubrication on a lasting basis. Cationic recombinant 
SUPs as additives, however, go even beyond restoration to rejuvenation of the film, 
affording effective lubrication under conditions of reduced availability of naturally 
occurring proteins. On the basis of the cooperative layer-by-layer mechanism laid out 
here, cationic protein polyelectrolytes show great promise for a minimally interfering 
treatment of impaired biolubrication.
EXPERIMENTAL PART
Design, development and characterization of recombinant cationic proteins
Materials 
All chemicals were used as received without any further purification. The pUC19 
cloning vector, restriction enzymes, and GeneJETTM Plasmid Miniprep kit were 
purchased from Fermentas (St. Leon-Rot, Germany). T4 DNA ligase and antarctic 
phosphatase were obtained from New England Biolabs (Ipswich, MA). Digested 
DNA fragments were purified using QIAquick® spin miniprep kits from QIAGEN, 
Inc. (Valencia, CA). E.coli XL1-Blue competent cells for plasmid amplification were 
purchased from Stratagene (La Jolla, CA). E.coli BLR(DE3) competent cells were 
purchased from Novagen Inc. (San Diego, CA). Oligonucleotides for sequencing were 
ordered from Sigma-Aldrich (St. Louis, MO). A-cyano-4-hydroxycinnamic acid and 
internal standards trypsinogen and enolase for mass spectrometry were purchased 
from LaserBio Labs (Sophia-Antipolis, France). Ultrapure water, resistivity > 18 
MW·cm, was used for all experiments. 
Gene oligomerization and expression vector construction 
Integrity of the DNA sequence was verified by sequencing of coding and 
complementary DNA strand after each cloning step (SequenceXS, Leiden, The 
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Netherlands). SUP monomer gene SUP K9, encoding for the polypeptide [GVGVP 
(GKGVP)9], was ordered from Entelechon (Regensburg, Germany) and was delivered 
in the pEN vector. The gene sequence and the respective amino acid sequence of 
the monomer are shown in supplementary Figure S1. As the recognition sites of the 
restriction endonucleases PflMI and BglI had to be preserved, one valine residue per 
ten pentapeptide repeats was incorporated instead of a lysine residue. All cloning 
steps were performed according to standard molecular biology methods. SUP K9 was 
transferred into the standard cloning vector pUC19, digested with EcoRI and HinDIII. 
Plasmids were isolated and positive clones were verified by plasmid digestion with 
EcoRI and HinDIII and subsequent gel electrophoresis. Gene oligomerization was 
performed as described by Chilkoti and co-workers.[23] Genes of correct length were 
identified by gel electrophoresis following plasmid digestion with EcoRI and HinDIII 
(supplementary Figure S2) and by sequencing (ServiceXS, Leiden, The Netherlands).
Genes coding for K36 and K72 were cloned into the expression vector pET25b(+)-
SfiIHis6 as described before.[16] Positive clones were identified by gel electrophoresis 
following plasmid digestion with EcoRI and HinDIII and by sequencing.
Protein expression and purification
E.coli BLR (DE3) cells were transformed with pET25b(+)-SfiIHis6 containing the 
respective SUP genes. For protein production, Terrific Broth medium (for 1 L, 12 
g tryptone and 24 g yeast extract) enriched with phosphate buffer (for 1 L, 2.31 
g potassium phosphate monobasic and 12.54 g potassium phosphate dibasic) and 
glycerol (4 mL per 1 L TB), and supplemented with 100 µg/mL ampicillin was 
inoculated with an overnight starter culture to an initial optical density at 600 nm 
(OD600) of 0.1 and incubated at 37 °C with orbital agitation at 250 rpm until OD600 
reached 0.7. Cultures were shifted to 30°C and continued for additional 16 h. Cells 
were subsequently harvested by centrifugation (7,000 x g, 20 min, 4 °C), resuspended 
in lysis buffer (10 mM TrisHCl buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole) 
to an OD600 of 100 and disrupted with a constant cell disrupter (Constant Systems 
Ltd., Northands, UK). Cell debris was removed by centrifugation (40,000 x g, 90 
min, 4 °C). Proteins were purified from the supernatant under native conditions by 
Ni-sepharose chromatography (GE Healthcare). Protein-containing fractions were 
dialyzed extensively against ultrapure water (resistivity >18 MΩ cm). Purified proteins 
were frozen in liquid nitrogen, lyophilized and stored at -17 °C until further use.
Protein characterization
Concentrations of purified SUPs were determined by measuring absorbance at 280 
nm on a SpectraMax M2 (Molecular Devices, Sunnyvale, CA). Protein purity was 
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determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on a 12% polyacrylamide gel according to Laemmli.[24] Gels were stained with 
coomassie staining solution (40% methanol, 10% glacial acetic acid, 1 g/L Brilliant 
Blue R250).  Photographs of the gels were taken with a LAS-3000 Image Reader 
(Fuji Photo Film (Europe) GmbH, Dusseldorf, Germany) (supplementary Figure 
S3a). Both K36 and K72 showed reduced electrophoretic mobility compared to a 
commercial molecular weight standard, a well-known phenomenon for elastin-like 
polypeptides.[23,25] Mass spectrometric analysis was performed using a 4800 MALDI-
TOF/TOF Analyzer (Applied Biosystems, Foster City, CA, USA) in the linear 
positive mode. The protein samples were mixed 1:1 v/v with a recrystallized a-cyano-
4-hydroxycinnamic acid matrix (10 mg/mL in 50% ACN and 0.1% TFA, LaserBio 
Labs). Mass spectra were analyzed and calibrated internally with the Data Explorer 
software, version 4.9 (Applied Biosystems, Foster City, CA, USA). Trypsinogen 
(MW = 23980) and enolase (MW = 46672) were used as calibration standards for 
K36 (expected MW = 18,888) and K72 (expected MW = 36,313), respectively. Mass 
spectra yielded sharp peaks for both variants (supplementary Figure S3 b and c). 
Determined masses were 18,932 +/- 20 Da for K36 and 36,330 +/- 30 Da for K72. 
Saliva collection
Human whole saliva from twenty healthy volunteers (10 men, 10 women, average 
age 30 ± 8 years) was collected into ice-chilled cups after stimulation of salivary flow 
by chewing Parafilm®. Volunteers gave their informed consent to saliva donation, 
in agreement with the guidelines set out by the Medical–Ethical-Committee at the 
University-Medical-Center-Groningen, The Netherlands. After saliva was pooled 
and centrifuged at 12,000 g, 15 min, 4°C, phenylmethylsulfonylfluoride was added to 
a concentration of 1 mM as a protease inhibitor. The solution was again centrifuged, 
dialyzed for 24 h, 4°C against demineralized water, and freeze-dried for storage. 
Lyophilized stock was prepared by mixing freeze-dried material originating from 2 L of 
saliva. Reconstituted saliva was prepared from the lyophilized stock by dissolution of 
1.5 mg/mL in buffer (2 mM potassium phosphate, 1 mM CaCl2, 50 mM KCl, pH 6.8). 
Quartz crystal microbalance with dissipation monitoring (QCM-D)
Structural softness and formation kinetics of SCFs were studied using a QCM-D 
device, model Q-sense E4 (Q-sense, Gothenburg, Sweden). Au-coated quartz 
crystals with 5 MHz were used as substrata. Before each experiment, crystals were 
cleaned by 10 min UV/ozone treatment, followed by immersion into a 3:1:1 mixture 
of ultrapure water, NH3 and H2O2 at 70°C for 10 min, drying with N2 and another 
UV/ozone treatment. The QCM-D chamber is disc-shaped with the inlet and outlet 
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facing the crystal surface. The chamber was perfused with buffer by a peristaltic 
pump (Ismatec SA, Glattbrugg, Switzerland). When stable base lines for both 
frequency and dissipation at third harmonics were achieved, saliva was introduced. 
Saliva was perfused through the chamber at 25°C for 2h at a flow rate of 50 mL/
min, corresponding with a shear rate of 3 s-1 after which the chamber was perfused 
with buffer or 0.05% w/v of either K72 or K36 for 2 min, followed by another 2 h 
of salivary flow. In between steps, the chamber was perfused with buffer for 15 min. 
The shear rate in the QCM-D represents a low oral salivary flow.[26] Frequency and 
dissipation were measured real-time during perfusion. 
After experiments, crystals were removed from the QCM-D and immediately 
used for further experiments. When needed for timing, saliva-coated Au crystals were 
kept hydrated in a closed environment with 100% humidity.
Colloidal Probe Atomic Force Microscopy
Friction force, surface topography and repulsive force range toward a colloidal[27] 
AFM probe were measured in buffer with an AFM (Nanoscope IV Dimensiontm 
3100) equipped with a Dimension Hybrid XYZ SPM scanner head (Veeco, New 
York, USA) on the differently adsorbed SCFs. Rectangular, tipless cantilevers were 
calibrated for their torsional and normal stiffness using AFM Tune IT v2.5 software.
[28] The normal stiffness (Kn) was between 0.01 - 0.04 N/m and the torsional stiffness 
(Kt) between 2 - 4 x 10
-9 N m/rad. Subsequently, a silica particle of 4.74 μm diameter 
(d) (Bangs laboratories, Fishers, IN, USA) was glued to a cantilever with an epoxy 
glue (Pattex, Brussels, Belgium). The deflection sensitivity (α) of the colloidal probe 
was recorded at a constant compliance with bare crystal in buffer to calculate the 
normal force (Fn) applied using
                    (2)
where ΔVn is the voltage output from the AFM photodiode due to normal deflection 
of the colloidal probe. The torsional stiffness and geometrical parameters of the 
colloidal probe were used to calculate the friction force (Ff) according to
   
         (3)          
                                                                
where t is the thickness of the cantilever, δ is the torsional detector sensitivity of 
the AFM and ΔVL corresponds to the voltage output from the AFM photodiode due 
to lateral deflection of the probe.[19,29] Lateral deflection was observed at a scanning 
angle of 90 degrees over a scan area of 5x5 µm2 and a scanning frequency of 1 Hz. 
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The colloidal probe was incrementally loaded and unloaded up to a maximal 
normal force of 35 nN. At each normal force, 10 friction loops were recorded to yield 
the average friction force. Repulsive force-distance curves between a colloidal probe 
and the films were obtained at a trigger threshold force of 10 nN and at an approach 
and retraction velocity of 10 µm s-1. The repulsive force range (D) was determined at 
a point where the colloidal tip starts experiencing the repulsive force > 1 nN between 
the two interacting surfaces. 
X-ray Photoelectron Spectroscopy (XPS)
Glycosylation of the adsorbed SCFs was determined by using XPS (S-probe, Surface 
Science Instruments, Mountain View, CA, USA). Films adsorbed on crystals as 
removed from the QCM-D chamber, were dried in the pre-vacuum chamber of
the XPS, and then subjected to a vacuum of 10-7 Pa. X-rays (10 kV, 22 mA, spot 
size 250 x 1000 mm) were produced using an aluminum anode. Scans in the binding 
energy range of 1-1100 eV were made at low resolution (pass energy 150 eV). The 
area under each peak was used to yield elemental surface concentrations for C, O, 
N, and Au after correction with sensitivity factors provided by the manufacturer. 
The O1S peak was split into three components for oxygen involved in amide groups 
(C=O-N; 531.3 eV), carboxyl groups (C-O-H; 532.7 eV) and oxygen arising from 
the crystal. Accordingly, the fraction of the O1s peak at 532.7 eV (%O532.7) was used 
to calculate the amount of oxygen involved in glycosylated moieties (%Oglyco) and 
amides (%Oamides).
%Oglyco =  %O532.7 * %Ototal                                                        (4) 
%Oamide = %O531.3 * %Ototal                                                            (5)
where %Ototal is the total percentage of oxygen.
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SUPPLEMENTARY INFORMATION
EcoRI                                       PflMI
A ATT CAT ATG GGC CAC GGC GTG GGT GTT CCG GGC AAA GGT GTT CCG GGT AAA GGT GTG CCG
                                                     G      V       G      V      P      G       K       G      V      P      G       K       G      V       P     
GGC AAA GGT GTT CCT GGT AAA GGT GTG CCG GGT AAA GGT GTG CCG GGT AAA GGT GTA CCA
   G       K      G      V      P      G       K      G       V       P      G       K       G      V       P      G       K      G      V      P   
                                                                                                                                            BglI                         HindIII
GGT AAA GGT GTT CCG GGT AAA GGC GTT CCG GTT AAA GGT GTG CCG GGC GGG CTG GAA TA
   G      K      G       V      P       G      K       G      V       P      G       K      G      V      P
Figure S1. Recombinant supercharged unfolded proteins: Monomer gene SUP K9. Gene 
sequence and corresponding polypeptide sequence in amino acid one-letter code. Recognition 
sites for the restriction enzymes EcoRI, PflMI, BglI, and HindIII are underlined.
Figure S2. Gel electrophoresis of SUP genes encoding for positively supercharged elastin-
like polypeptides. PUC vectors containing the SUP genes were digested with EcoRI and 
HinDIII and separated on a 1% agarose gel. DNA bands were visualized by ethidium bromide 
staining. Digestion produced a vector fragment of 2,635 bp and a SUP gene fragment (size 
in bp is depicted on the right). n: number of repeats; K: lysine ; 9-72: number of charges in 
respective elastin-like polypeptide; M: size standard.
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Figure S3. Characterization of recombinant supercharged unfolded proteins.
(a) Gel electrophoresis: Purified proteins were separated on a 12% SDS-PAGE gel and 
stained with Coomassie brilliant blue R250. M: size standard. Expected sizes were 18.9 kDa 
(K36) and 36.3 kDa (K72); (b-c) MALDI-TOF mass spectra. (b) K36 with internal standard 
trypsinogen (MW = 23981) and (c) K72 with internal standard enolase (MW = 46672). I = 
absolute intensity.
Figure S4. Surface topography of the surfaces as imaged by colloidal probe AFM. (a) Bare 
Au coated QCM crystal ; (b) SCF in absence of adsorbed recombinant cationic proteins; (c) 
SCF with adsorbed K36 and after renewed exposure to saliva; (d) SCF with adsorbed K72 and 
after renewed exposure to saliva; (e) height as a function of width of the globular structures 
found in the different adsorbed films. 
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% Au-coated QCM crystal SCF without recombinants
SCF with 
K72 SCF with K36
C 41.3 ± 1.5 62.9 ± 2.9 62.9 ± 2.9 56.4 ± 1.40
N Not detected 14.3 ± 1.2 13.9 ± 0.7 13.0 ± 0.4
O
Ototal 11.7 ± 1.5 22.6 ± 1.8 24.1 ± 2.8 22.3 ± 1.9
%O 532.7*Ototal Not detected 5.8 ± 0.8 7.19 ± 0.6 6.9 ± 0.3
%O 531.2*Ototal Not detected 15.7 ± 1.7 16.8 ± 2.1 15.3 ± 1.5
Table S1. Elemental composition of the bare Au coated QCM crystals with and without an adsorbed 
SCF, and with SCF possessing adsorbed K36 or K72 after renewed exposure to saliva. ± indicates 
standard deviation over three measurements. 
Figure S5. Zeta potentials of the SCFs in absence and presence of adsorbed SUPs. Silica 
spheres (diameter 970 nm) were coated with SCF by suspending in saliva for 2 h. Subsequently, 
the spheres were suspended in buffer or recombinant K36 or K72 solutions (0.05% w/v) for 
2 min. After each coating step, the spheres were rinsed with buffer for 10 min. The zeta 
potential of the different spheres was measured in buffer (2 mM potassium phosphate, 1 mM 
CaCl2, 50 mM KCl, pH 6.8) employing a Zetasizer nano series (Model Number ZEN3600, 
Malvern Ltd, UK). Error bars represent the standard deviation over three measurements with 
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Supercharging of Proteins by Means of a Highly 
Charged Tag
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In this work we present an alternative method for the fabrication of supercharged 
proteins, where the protein of interest is fused to a genetically engineered polypeptide 
tag with high charge density and tightly controlled distribution of charges along 
the backbone. In contrast to post-translational, chemical modification and genetic 
modification of surface-exposed amino acids, this method obviates the need to 
modify the protein of interest itself. By adjusting the length of the charged tag, we 
can gradually tune the overall charge of the fusion protein. Tags carrying between 
-144 and +72 charges were fused to green fluorescent protein (GFP). All variants 
were successfully produced in E.coli and purified as fluorescently active proteins. 
It was demonstrated that the charged tag allows incorporation of proteins with a 
low overall net charge into electrostatically mediated layer-by-layer assemblies. 
Uptake of the resulting capsules by cultured mammalian cells could be followed with 
fluorescence microcopy.
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Methods to significantly alter a protein’s overall charge are known since decades,[1]
[2] but gained increased attention in recent years due to possible new applications in 
biotechnology and biomedicine.[3,4] A protein’s net charge can be altered by post-
translational, chemical modification or by genetic engineering. Post-translational, 
chemical modification takes advantage of reactive, solvent-exposed amino acid 
residues, like glutamic or aspartic acid and lysine. Charges can be neutralized 
by acetylation of lysine residues or by amidation of carboxylic acid groups, for 
example, to increase a protein’s net negative or positive charge, respectively.[5,6] 
Highly negatively charged derivatives of an industrially relevant enzyme, α-amylase, 
showed increased resilience against inactivation due to temperature elevation 
or addition of surfactants.[3,5] On the other hand, neutralization increases surface 
hydrophobicity and thus can render a protein more susceptible to aggregation.[7,8] 
Alternatively, the charge of a residue can be reversed to yield variants with a high 
net charge and a high charge density. The plasma protein bovine serum albumin 
(BSA), which is negatively charged at neutral pH and which contains a high number 
of reactive, surface-exposed amino acid residues, was chemically modified to yield 
highly positively and negatively charged variants.[9-11] Cationized BSA variants were 
successfully employed as biocoatings for the immobilization of lipid vesicles and 
bacterial biofilms and for cell adhesion.[12-14]. Furthermore, cationized BSA was used 
as efficient vehicle for gene delivery.[11] A major drawback of chemical modification 
is its randomness which results in a mixture of proteins with different net charges. 
Controlled reaction schemes and elaborate purification strategies were necessary to 
yield protein samples with low charge distributions.[11]
As an alternative to post-translational, chemical modification, the net charge of a 
protein can be dramatically increased by genetic engineering. Surface-exposed amino 
acids were mutated individually to create superpositive and supernegative variants of 
green fluorescent protein (GFP) and glutathione-S-transferase (GST).[15] In most cases 
the function of the protein, i.e. fluorescence or catalytic activity, was not impaired.
[15] Positively supercharged variants of GFP were shown to penetrate mammalian cell 
membranes.[16] Due to electrostatic interactions, these proteins were able to complex 
with silencing RNA and plasmid DNA and to transfect a variety of mammalian cell 
lines.[16] Moreover, functional proteins that were fused to a superpositively charged 
GFP variant were successfully delivered into mammalian cells in vitro and in vivo.[17] 
Interestingly, supercharged variants of GFP, GST and streptavidin were highly resistant 
to thermally induced aggregation.[15] This stabilizing effect was mainly attributed to 
repelling forces between proteins due to the presence of surface charges, inhibiting 
irreversible aggregation and enabling refolding after denaturation.[15] It has to be 
taken into account, however, that salt bridges between oppositely charged residues 
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convey conformational stability to the tertiary structure.[18,19] Deleting or inversing 
the charge of an amino acid can therefore destroy stabilizing salt bridges, which 
might counteract the gain in aggregation resistance.[20] Consequently, supercharging 
of a protein by genetic mutation of solution-exposed amino acids requires careful 
examination of the crystal structure to identify charged amino acid residues on the 
protein surface, mutation and shuffling of the gene sequence, and expression and 
screening for functional variants.[4] 
In this work, we present an alternative strategy to modify the overall charge of a 
protein of interest. By genetic engineering, the protein is equipped with a supercharged 
polypeptide tag. This enables us to tune the overall charge of the protein to basically 
any desired value by adjusting the length of the tag, while obviating modification of 
the protein itself. For tag design we chose elastin-like polypeptide (ELP) as basic 
sequence. The suitability of ELPs as materials for biomedical applications was 
demonstrated in a number of publications. ELPs were employed as hydrogels for 
biosurface and tissue engineering and for controlled release.[21-24] Furthermore, ELPs 
were used for delivery of drugs, peptides, proteins and DNA.[23,25,26] We have shown 
earlier that ELPs can be positively and negatively supercharged by introducing a 
lysine or glutamic acid residue at the fourth position of the repetitive pentapeptide 
sequence.[27] In this work we demonstrate the supercharging of a model protein, GFP, 
by means of fusion with charged variants of ELP.  
RESULTS AND DISCUSSION
Preparation and Characterization of supercharged GFP-ELP fusion proteins
Genes encoding for cationic and anionic supercharged protein tags of different 
lengths were generated by recursive directional ligation of the elp monomer gene 
(Figure S1).[28] An ELP monomer consists of 10 repeating units of the pentapeptide 
sequence GXGVP, with G denoting the amino acid glycine, V valine, P proline and 
X either glutamic acid (E), lysine (K) or V. To preserve the restriction site that is 
needed for multimerization, V is inserted at position X in one out of ten pentapeptide 
repeats (Figure 1 b). After multimerization, the elp genes were cloned into a bacterial 
expression vector containing the gfp gene and a sequence encoding a hexahistidine 
tag for affinity purification. Gfp encodes GFP plus, a variant of enhanced green 
fluorescent protein, hereafter named GFP (Figure S3). We realized fusion variants 
of GFP with supercharged protein containing between nine and 144 negative and 
between nine and 72 positive charges. In this work, GFP-Ex and GFP-Kx denote 
GFP with anionic and cationic tags, respectively, with x displaying the number of 
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charged residues in the tag. All variants were successfully expressed in and purified 
from E.coli cells. Typically, a 50 mL culture yielded up to 20 mg of purified protein. 
Protein integrity and purity was confirmed by gel electrophoresis (Figure 1 c) and 
mass spectrometry (Figure 2). Values determined by mass spectrometry were is good 
agreement with the masses that were calculated based on the amino acid sequence 
(Table S1). For all variants, GFP was found to be fluorescent. Fluorescence spectra 
were recorded for GFP, GFP-K72 and GFP-E72 (Figure 3). GFP fluorescence was not 
decreased or shifted, indicating that even the long positively and negatively charged 
tags did not interfere with GFP function.
Figure 1. GFP fusion variants of supercharged elastin-like proteins (ELPs). Left: negatively 
charged ELPs; right: positively charged ELPs. a) Schematic representation of GFP-ELP 
fusion proteins. GFP (green) shows the characteristic beta-barrel structure, whereas the ELP 
is presented as an extended coil without exhibiting a defined secondary or tertiary structure. b) 
Amino acid one letter code of the ELP fusion protein, where n is the number of ELP monomer 
repeats. The position of GFP close to the N-terminus is indicated in green. c) GFP-ELP fusion 
proteins separated on a 12% SDS-PAGE gel and stained with Coomassie brilliant blue R250.
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Figure 3. Fluorescence spectra 
of GFP and GFP-ELP variants 
GFP-K72 and GFP-E72 upon 
excitation at 488 nm. Spectra are 
averages of three measurements.
Figure 2. MALDI-TOF mass spectra of supercharged elastin-like proteins fused to GFP. a) 
GFP-E9; b) GFP-E18; c) GFP-E36; d) GFP-E72; e) GFP-E144; f) GFP-K9; g) GFP-K18; h) 
GFP-K36; i) GFP-K72.  Internal standards are enolase (a, b, g), bovine serum albumin (c-e, 
h, i) and trypsinogen (f).
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We have shown that we can supercharge GFP by expression as a fusion protein 
with charged ELP, following a simple cloning step. We were able to realize GFP-ELP 
fusion variants carrying up to 144 negative charges and up to 72 positive charges, while 
preserving the fluorescence of GFP.  To our knowledge, these are the highest number 
of charges realized to date by genetic engineering. The highest net charges achieved 
by genetic mutation of solvent-exposed amino acids were +48 and -30 charges for 
a superfolder variant of GFP (stGFP).[15] As folded proteins contain only a limited 
number of solvent-exposed amino acids, this method is restricted as to the net surface 
charge values that can be realized. Furthermore, not all surface-exposed amino acids 
can be mutated without impairing conformational stability and function.[15] Fusing a 
protein to a charged tag, on the other hand, enables us to fabricate functional proteins 
with virtually any desired net charge.  
CAPSULE PREPARATION AND UPTAKE
A charged tag allows for incorporation of the tagged protein into supramolecular 
structures that are assembled by means of electrostatic interactions. In this way, such 
structures can be easily equipped with a desired function (fluorescence in this case) 
without the need of an extra coupling step. A well-known example for electrostatically 
assembled structures are polyelectrolyte capsules, which exhibit great potential as 
carriers for intracellular delivery of biotherapeutics.[29,30] For loading of cargo, either 
the capsule cavity or the capsule wall can be addressed.  While bioactive molecules, 
like enzymes, antigens and peptides, were mostly loaded into the capsule cavity,[29,31] 
charged nanoparticles, such as magnetic nanoparticles[32,33], quantum dots[34,35], and 
noble metal nanoparticles[36,37], were successfully incorporated into the capsule wall. 
Furthermore, polyelectrolyte capsules containing layers of two enzymes, glucose 
oxidase and horseradish peroxidase, with high natural net charge (isoelectric points 
4.2 and 8.8) were fabricated, and the thus incorporated enzymes showed no loss of 
activity.[38] 
We therefore decided to fabricate hollow polyelectrolyte capsules composed of 
dextran sulfate (DEXS) and poly(L-arginine) (pARG), with one pARG layer being 
replaced by GFP-K72. In collaboration with Dr. Loretta L. del Mercato from the 
University of Salento (Italy) and Prof. Wolfgang Parak from the University of Marburg 
(Germany), capsules were prepared and characterized as described in chapter 2. In 
short, ten layers were assembled on a sacrificial CaCO3 core template by the layer-by-
layer technique in the following order: (DEXS/pARG)3(DEXS/GFP-K72)(DEXS/
pARG). After core removal, the hollow capsules could be visualized by confocal 
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fluorescence microscopy, proving that fluorescence of GFP was preserved (Figure 4). 
The capsules had a size between 2.8 and 3.3 µm, comparable to the core template, 
and retained their spherical shape after core removal, indicating that incorporation of 
GFP-K72 did not destabilize the capsule wall (Figure 4). 
Figure 4. Hollow polyelectrolyte capsules functionalized with GFP-K72. Capsules were prepared from 
dextran sulfate and poly(L-arginine) with the layer-by-layer technique and are shown after core removal. 
a) Fluorescence image; b) transmission image; c) overlay; d)-f) magnifications of (a-c). Scale bars: 10 
µm (a-c) and 3 µm (d-f).
Next, cellular uptake of the capsules was studied in collaboration with Dr. Pilar 
Rivera Gil and Prof. Parak from the University of Marburg. Capsules were incubated 
with MDA-MB-231 P48, a human breast carcinoma cell line, and capsule uptake was 
followed by confocal fluorescence microscopy, taking advantage of GFP’s inherent 
fluorescence. Directly after addition to the cell culture, capsules aggregated in clusters 
(Figure 5a). This phenomenon can be explained by the polyionic nature of the capsules, 
which tend to adsorb proteins present in the cell culture medium, thereby stimulating 
aggregation of the capsules.[31] After 2 h incubation, capsules were attached to the cell 
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membrane, probably due to electrostatic interaction between the negatively charged 
membrane and the positively charged outermost layer of the capsule (Figure 5a). 
Most capsules were found to colocalize with the cell interior 7 h after addition, and 
fluorescence started to spread across the cell (Figure 5c). This effect was even more 
pronounced after 27 h of incubation (Figure 5d). Although the size of the fluorescent 
spots partly decreased over time, fluorescence still seemed to be restricted to defined 
areas, even after 27 h, indicating localization in intracellular compartments. This 
finding is in agreement with previous reports, which stated that micrometer-sized 
capsules were deformed upon uptake and found in acidic intracellular compartments 
after internalization.[29,39-43] GFP fluorescence significantly decreased after 31 h of 
incubation (Figure 5e) and was hardly distinguishable from background fluorescence 
of untreated cells after 46 h (Figure 5f, untreated cells not shown). Whether the 
observed decrease in fluorescence is due to dilution or inactivation of GFP in the 
acidic intracellular compartment, needs to be investigated.
Figure 5. Studying the uptake of capsules by mammalian cells. A culture of human breast carcinoma 
cells was incubated with GFP-K72-functionalized capsules. Images were obtained a) 0 h; b) 2 h; c) 7 
h; d) 27 h; e) 31 h; f) 46 h after addition of capsules to the cell culture. Note that images a) and b) were 




In this work, we demonstrated that proteins can be supercharged by equipping 
them with a positively or negatively charged polypeptide tag. Expression as fusion 
proteins eliminated the need of an extra chemical coupling step for functionalization. 
We realized GFP-charged tag fusion proteins with up to 144 negative and up to 72 
positive charges. 
Furthermore, we successfully incorporated the superpositive variant GFP-K72 into 
the wall of polyelectrolyte multilayer capsules by means of electrostatic interactions, 
while maintaining the fluorescence of GFP. In initial experiments, uptake of these 
capsules by mammalian cancer cells was followed by fluorescence microscopy. For 
capsule preparation, we have chosen GFP with a relatively long positively charged 
tag. In future experiments it remains to determine the minimum tag length that 
is needed for stable incorporation of the tagged protein into the capsule wall and 
whether a cationic or an anionic tag should be preferred. Moreover, the fate of the 
capsules and the incorporated proteins after uptake need to be investigated in more 
detail. We are therefore planning to fabricate capsules containing two fluorescent 
proteins – GFP and mCherry, a red fluorescent protein. As the absorption spectrum 
of mCherry overlaps with the emission spectrum of GFP, mCherry can serve as an 
acceptor for the green GFP emission.[44,45] Therefore, fluorescence resonance energy 
transfer (FRET) will be observed between GFP and mCherry, provided they are in 
close proximity, as is the case when both proteins are incorporated into the capsule 
wall. Detection of a FRET signal, i.e. emission of red fluorescence by mCherry upon 
excitation of GFP, will therefore indicate an intact capsule. Upon disintegration of 
the capsule, the FRET signal will decrease due to release of the proteins, while their 
individual fluorescence can still be observed.
Taken together, we have demonstrated that charged tags provide the means to equip 
polyelectrolye capsules with a functional protein. Furthermore, we believe that this 
concept can be expanded to the functionalization of surfaces or other electrostatically 
assembled structures, like polyplexes, for example.[46,47] 
EXPERIMENTAL PART
Materials
The pUC19 cloning vector, restriction endonucleases, and GeneJETTM Plasmid 
Miniprep kit were purchased from Fermentas (St. Leon-Rot, Germany). T4 DNA 
ligase and antarctic phosphatase were purchased from New England Biolabs (Ipswich, 
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MA). Digested DNA fragments were purified using QIAquick® spin miniprep kits 
from QIAGEN, Inc. (Valencia, CA). E.coli XL1-Blue competent cells were purchased 
from Stratagene (Cedar Creek, TX). The pET-25b(+) vector and E.coli BLR(DE3) 
competent cells were purchased from Novagen Inc. (San Diego, CA). Oligonucleotides 
were ordered from Sigma-Aldrich (St. Louis, MO). Elastin-like polypeptide monomer 
genes were ordered from Entelechon (Regensburg, Germany). BactoTM tryptone and 
BBLTM yeast extract were purchased from Becton, Dickinson and Co. (Sparks, MD). 
Potassium phosphate monobasic, potassium phosphate dibasic, sodium phosphate 
monobasic, sodium phosphate dibasic, sodium chloride, glycerol, glycine, acetic 
acid (glacial, anhydrous), ammonium persulfate and ethylenediaminetetraacetic acid 
were purchased from Merck KGaA (Darmstadt, Germany). tris(hydroxymethyl)
amino methane and N,N,N’,N’-Tetramethylethylenediamine were purchased 
from Acros Organics (Geel, Belgium). Methanol was purchased from Lab-Scan 
(Gliwice, Poland). Acrlyaminde:N,N’-methylene-bis-acrylamide and Tween20 were 
purchased from Bio-Rad Laboratories (Hercules, CA). Nunc Immobilizer Amino 
F96 clear plates were purchased from Nunc (Roskilde, Denmark). Antibodies Mouse 
monoclonal [6AT316] to GFP and Rabbit polyclonal Secondary Antibody to Mouse 
IgG - H&L (HRP) were purchased from Abcam (Cambridge, United Kingdom). 
Anti-His antibody was purchased from GE Healthcare (Buckinghamshire, United 
Kingdom). QuantaBlu™ Fluorogenic Peroxidase Substrate Kit was purchased from 
Thermo Scientific (Rockford, IL). Sodium dodecyl sulfate was purchased from BDH 
(Poole, United Kingdom). Carbenicillin, imidazole, Brilliant Blue R250 and bovine 
serum albumin were purchased from Carl Roth (Karlsruhe, Germany). 3,5 dimethoxy-
4-hydroxycinnamic acid and internal standards bovine serum albumin, yeast enolase 
and trypsinogen for mass spectrometry were purchased from LaserBio Labs (Sophia-
Antipolis, France). All chemicals were used as received. Ultrapure water with a 
resistivity greater than 18.2 MW cm was used for all experiments. PGFP was a kind 
gift from Prof. D. Hilvert, Swiss Federal Institute of Technology, Zurich, Switzerland. 
Gene oligomerization
Monomers of the cationic and anionic ELP genes (K9 and E9) were ordered from 
Entelechon and were delivered in the pEN vector. Gene sequences and respective 
amino acid sequences of monomers are shown in Figure S1. As the recognition sites 
of the restriction enzymes PflMI and BglI had to be preserved, one valine residue per 
ten pentapeptide repeats was incorporated instead of a lysine or glutamic acid residue. 
The ELP gene was excised from the pEN vector by digestion with EcoRI and HinDIII 
and run on a 1% agarose gel in TAE buffer (per 1L, 108 g Tris base, 57.1 mL glacial 
acetic acid, 0.05 м EDTA, pH 8.0). The band containing the ELP gene was excised 
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from the gel and purified using a spin column purification kit (QIAGEN). PUC19 was 
digested with EcoRI and HinDIII and was subsequently dephosphorylated. The vector 
was purified by agarose gel extraction following gel electrophoresis. The linearized 
pUC vector and the ELP-encoding gene were ligated and transformed into XL1-
Blue cells. For transformation, 20 µL of chemically competent E.coli XL1-Blue cells 
were combined with 5 µL of the ligation mixture and further treated according to the 
manufacturer’s protocol. Cells were spread on Lysogeni broth (LB) agar plates (for 1 
L, 10 g BactoTM tryptone, 5 g BBLTM yeast extract, 5 g NaCl, 15 g agar) supplemented 
with 100 µg/mL carbenicillin, and incubated overnight (o/n) at 37ºC. Colonies were 
picked and grown in 6 mL LB media (for 1 L, 10 g BactoTM tryptone, 5 g BBLTM 
yeast extract, 5 g NaCl) supplemented with 100 µg/mL carbenicillin overnight, and 
plasmids were isolated using the GeneJET Plasmid Miniprep kit. Positive clones 
were verified by plasmid digestion with EcoRI and HinDIII and subsequent gel 
electrophoresis. The DNA sequence of putative inserts was further verified by DNA 
sequencing (SequenceXS, Leiden, The Netherlands). Gene oligomerization was 
performed as described by Chilkoti and co-workers (Figure S2).[48] 
Expression vector construction
The expression vector pET 25b(+) was modified by cassette mutagenesis for 
incorporation of a unique SfiI recognition site as described before.[27,48] The modified 
pET 25b(+) vector (hence called pET-SfiI from here on) was further digested with 
XbaI and NdeI, dephosphorylated and purified using a microcentrifuge spin column 
kit. The gfp gene including the ribosomal binding site was excised from the pGFP 
vector by digestion with XbaI and SacI, and the excised gene (747 bp) was purified 
by agarose gel extraction following gel electrophoresis. A linker sequence that 
would connect gfp and the SfiI restriction site was constructed in the following way: 
Oligonucleotides linker_sens (cggtgtagtc ggtttagttc ccagaggaag tca) and linker_
antisens (tatgacttcc tctgggaact aaaccgacta caccgagct), both 5’-phosphorylated, were 
mixed in equimolar ratios, incubated at 90°C for 1 h and then cooled down stepwise 
to 20°C for annealing (1°C per 3 min). The resulting linker contained overhangs 
corresponding to a SacI and an NdeI restriction site, respectively. pET-SfiI, the insert 
containing gfp and the linker were ligated, yielding pET-gfp-SfiI. For insertion of 
ELP genes, pET-gfp-SfiI was digested with SfiI, dephosphorylated and purified using 
a microcentrifuge spin column kit. The respective ELP gene was excised from the 
pUC19 vector by digestion with PflMI and BglI, and the excised gene was purified 
by agarose gel extraction following gel electrophoresis. The linearized vector and the 
insert containing the ELP gene were ligated, transformed into XL1-Blue cells, and 
screened as described above. 
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Protein expression and purification
E.coli BLR (DE3) cells (Novagen) were transformed with the pET-SfiI expression 
vectors containing the respective ELP genes. For protein production, Terrific Broth 
medium (for 1 L, 12 g tryptone and 24 g yeast extract) enriched with phosphate buffer 
(for 1 L, 2.31 g potassium phosphate monobasic and 12.54 g potassium phosphate 
dibasic) and glycerol (4 mL per 1 L TB) and supplemented with 100 µg/mL ampicillin, 
was inoculated with an overnight starter culture to an initial optical density at 600 nm 
(OD600) of 0.1 and incubated at 37°C with orbital agitation at 250 rpm until OD600 
reached 0.7. Protein production was induced by a temperature shift to 30°C. Cultures 
were then continued for additional 16 h post-induction. Cells were subsequently 
harvested by centrifugation (7,000 x g, 20 min, 4ºC), resuspended in lysis buffer (50 
mм sodium phosphate buffer, pH 8.0, 300 mм NaCl, 20 mм imidazole for E variants 
or 10 mм TrisHCl buffer, pH 8.0, 300 mм NaCl, 20 mм imidazole for K variants) to 
an OD600 of 100 and disrupted with a constant cell disrupter (Constant Systems Ltd., 
Northands, UK). Cell debris was removed by centrifugation (40,000 x g, 90 min, 4ºC). 
Proteins were purified from the supernatant under native conditions by Ni-sepharose 
chromatography (GE Healthcare). Product-containing fractions were pooled and 
dialyzed against Ultrapure water (>18 MΩ). K variants were further purified by affinity 
chormatography using a Heparin HP column (GE Healthcare), and E variants by anion 
exchange chromatography using a Q HP column (GE Healthcare). Protein-containing 
fractions were dialyzed extensively against ultrapure water (>18 MΩ). Purified proteins 
were frozen in liquid nitrogen, lyophilized and stored at -20ºC until further use.
Protein characterization
The concentrations of the purified ELPs were determined by measuring absorbance at 
280 nm using a spectrophotometer (SpectraMax M2, Molecular Devices, Sunnyvale, 
CA). Protein purity was determined by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) on a 12% polyacrylamide gel according to Laemmli[49] 
and subsequent copper (II) chloride staining as reported by Lee and coworkers.[50] 
Afterwards, gels were stained with coomassie staining solution (40% methanol, 10% 
glacial acetic acid, 1 g/L Brilliant Blue R250). Photographs of the gels before and 
after coomassie staining were taken with a LAS-3000 Image Reader (Fuji Photo Film 
(Europe) GmbH, Dusseldorf, Germany).
Mass spectrometric analysis was performed using a 4800 MALDI-TOF/TOF 
Analyzer (Applied Biosystems, Foster City, CA, USA) in the linear positive mode. The 
protein samples were mixed 1:1 v/v with a recrystallized a-cyano-4-hydroxycinnamic 
acid matrix (10 mg/mL in 50% ACN and 0.1% TFA, LaserBio Labs). Mass spectra 
were analyzed and calibrated internally with the Data Explorer software, version 4.9 
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(Applied Biosystems, Foster City, CA, USA). Trypsinogen (MW = 23,980), enolase 
(MW = 46,672) and bovine serum albumin (MW = 66,431) were used as calibration 
standards. 
Fluorescence spectra of GFP, GFP-K72 and GFP-E72 were recorded on a 
fluorimeter (SpectraMax M2, Molecular Devices, Sunnyvale, CA). GFP concentration 
in phosphate buffer solution (PBS) was determined by measuring absorbance at 488 
nm. Volumes were adjusted with PBS until absorbance at 488 nm was between 0.82 
and 0.85. Samples were diluted ten times in PBS for fluorescence measurements. 
Fluorescence spectra were recorded upon excitation at 488 nm. Measurements 
were carried out in triplicates and average fluorescence values were corrected for 
differences in absorbance according to
RFUcorr = RFUmeas · 0.84 / abs488,
with RFUcorr being the corrected relative fluorescence unit (RFU), RFUmeas the 
measured RFU, and abs488 the measured absorbance at 488 nm of the ten times 
concentrated solution. 
SUPPLEMENTARY DATA
Figure S1. Genes and corresponding polypeptide sequences of (a) ELP K9 (monomer lysine) and (b) 
ELP E9 (monomer glutamic acid). Recognition sites for the restriction enzymes EcoRI, PflMI, BglI, and 
HindIII are underlined.
b) ELP monomer glutamic acid (E9)
EcoRI                                             PflMI
A ATT CAT ATG GGC CAC GGC GTG GGT GTT CCG GGC GAA GGT GTT CCG GGT GAA GGT GTG CCG
                                                 G      V       G      V      P      G      E      G      V      P      G      E      G     V       P         
GGC GAA GGT GTT CCT GGT GAA GGT GTG CCG GGT GAA GGT GTG CCG GGT GAA GGT GTA CCA
   G      E      G      V      P      G      E      G       V      P      G       E      G      V      P       G      E      G      V      P    
                                                                                                                                         BglI                         HindIII
GGT GAA GGT GTT CCG GGT GAA GGC GTT CCG GTT GAA GGT GTG CCG GGC GGG CTG GAA TA
  G       E      G      V      P      G      E      G      V       P      G      E      G      V      P
a) ELP monomer lysine (K9)
EcoRI                                             PflMI
A ATT CAT ATG GGC CAC GGC GTG GGT GTT CCG GGC AAA GGT GTT CCG GGT AAA GGT GTG CCG
                                                 G      V       G      V      P      G      K      G      V      P      G      K      G     V       P     
GGC AAA GGT GTT CCT GGT AAA GGT GTG CCG GGT AAA GGT GTG CCG  GGT AAA GGT GTA CCA
   G      K      G      V      P      G      K      G      V      P      G      K       G     V       P      G       K      G      V      P   
                                                                                                                                       BglI                         HindIII
GGT AAA GGT GTT CCG GGT AAA GGC GTT CCG GTT AAA GGT GTG CCG GGC GGG CTG GAA TA
   G      K      G      V      P      G      K      G      V      P      G     K      G      V      P
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Figure S2. Gel electrophoresis of ELP genes. PUC vectors containing the ELP genes were digested 
with EcoRI and HinDIII and separated on a 1% agarose gel. DNA bands were visualized by ethidium 
bromide staining. Digestion produced a vector fragment of 2,635 bp and an ELP gene fragment (size 
in bp is depicted on the right). n = number of monomers with 10 pentapeptide repeats per monomer; 
E = negatively charged; K = positively charged; 9-144: amount of charges in respective elastin-like 
polypeptide; M: size standard.
Figure S3. Nucleotide sequence (a) and amino acid one letter code (b) of the green fluorescent protein 
variant used in this study.
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construct M calc* [Da] M ms#[Da]
GFP-E9 33,425.3 33,372 +/- 50
GFP-E18 37,790.0 37,725 +/- 50
GFP-E36 46,519.4 46,402 +/- 50
GFP-E72 63,978.2 63,893 +/- 50
GFP-E144 98,895.8 98,874 +/- 50
GFP-K9 33,416.8 33,381 +/- 50
GFP-K18 37,904.2 37,722 +/- 50
GFP-K36 46,485.5 46,377 +/- 50
GFP-K72 63,910.4 63,768 +/- 50
* average molecular weight calculated with ProtParam tool
# molecular weight determined by MALDI-TOF mass spectrometry
Table S1. Mass determination of GFP-ELP variants
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Biosensors based on semiconducting nanowire field-effect transistors (NW-FETs) 
show fast responses with high sensitivity and selectivity and are therefore promising 
candidates for the detection of disease-related markers.  The net charge of the 
analyte plays a crucial role in detection by these devices, as the electrical response is 
dependent on changes in the electric field close to the nanowire surface. Understanding 
the influence of analyte charge on the electric signal will help in improving these 
biosensors for in-vitro diagnostics. By genetic engineering, the overall charge of 
a protein can be substantially altered when equipped with a charged protein tag, 
while leaving the protein itself unchanged. Green fluorescent protein is an excellent 
model protein, because it exhibits a low net charge at physiological pH and binding 
to a surface or device can be detected by means of fluorescence. Highly negatively 
and positively charged variants of elastin-like polypeptide were expressed as fusion 
proteins with GFP. By changing the length of the supercharged tags, protein markers 
with varying tag charges (from -144 to +72) can be fabricated. Sensing experiments 
on nanowire-based devices demonstrate that already short tags with nine positive or 
negative charges render green fluorescent protein well detectable in NW-FETs. 
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Detection of disease-related markers has the potential to revolutionize medical 
diagnostics. These markers are small molecules, peptides, proteins or nucleic acids 
that are present in body fluids. Early-on stage detection will allow timely treatment, 
resulting in better prognosis, and has therefore fuelled tremendous efforts in 
biomedical research to identify disease-related markers. [1-6] To take advantage of 
these findings for diagnostic purposes, fast and reliable detection schemes are required 
that can detect marker molecules with high selectivity and sensitivity. Moreover, 
cancer as well as coronary and chronic inflammatory diseases show complex patterns 
of different markers in dependence of the course of the disease.[7-12] Therefore, a 
suitable detection scheme should be able to analyze multiple markers on the same 
array. Sensors based on semiconducting nanowires (NWs) in field effect transistors 
(FETs) are promising tools for the sensitive and selective detection of biomarkers 
like proteins,[13-16] DNA[17-19] and virus particles[20]. Furthermore, their potential for 
multiplexed detection was demonstrated.[14]
Detection of molecules by NW-FETs is based on the principle that a variation 
in the electric field or potential close to the NW surface results in a measureable 
conductivity change.[21] Consequently, the net charge of the analyte has substantial 
influence on the sensitivity of NW based detection schemes. It is therefore of great 
interest to study the impact of the analyte charge on the conductivity change.  Here, 
we present a new paradigm for probe design in which proteins with low net charge 
are genetically engineered to enhance their detectability in NW-FET based devices.
Two main strategies that change the overall charge of a protein were demonstrated in 
the literature so far. The first strategy relies on chemical posttranslational modification 
of amino acid residues on the surface of the protein. Lysine residues were chemically 
modified by acetylation or succinylation, whereas carboxyl groups were methylated.
[22,23] Another approach was demonstrated by the group of Liu. Instead of chemical 
alteration, they employed genetic modification of surface-exposed amino acids to 
create superpositive and supernegative variants of GFP, streptavidin and glutathione-
S-transferase, a process they referred to as “supercharging of proteins”.[24] While both 
methods lead to protein variants with high surface net charge, they might not be 
suitable to improve detection in biosensors, because binding of the analyte to the 
sensor is mediated by specific interaction with a capture molecule (e.g. a receptor or 
antibody in the case of proteins), which strongly relies on conservation of epitopes on 
the surface of the target. Consequently, exhaustive charge modification of the protein 
surface will impair recognition by commercially available antibodies. It was therefore 
our goal to increase the overall charge of a protein by means of a charged tag, leaving 
the protein itself unchanged. Furthermore, it is advantageous to choose a tag which is 
not prone to cross-recognition. In this respect, intrinsically disordered polypeptides 
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are promising candidates, as they lack any secondary or tertiary structure. We have 
shown earlier that elastin-like polypeptides (ELPs), which are unfolded below their 
lower critical solution temperature, can be positively or negatively supercharged by 
introducing a lysine or a glutamic acid residue at the fourth position of the repetitive 
pentapeptide sequence.[25] Moreover, we demonstrated the supercharging of green 
fluorescent protein (GFP) by means of fusion with charged variants of ELP (chapter 
4 in this thesis). By varying the length of the tag, the overall charge of the protein can 
be easily tuned. In this work we investigate the influence of the number of charges on 
the detection of GFP in a silicon NW-FET biosensor.
RESULTS AND DISCUSSION
As mentioned before, the charge of the analyte is a key factor for detection in sensors 
based on NW-FETs. In the case of sensing of DNA hybridization, the high overall net 
charge of DNA is taken advantage of, as DNA carries a negatively charged phosphate 
group at every nucleotide.[19] In contrast, the net charge of proteins varies substantially 
between different proteins, rendering their detection in NW-FET-based sensors a 
more demanding task. Moreover, about 84 % of all polypeptides contained in the 
Protein Data Bank (PDB) carry a net charge that ranges between – 10 and +10, i.e. 
they are only moderately charged at physiological conditions.[24] As NW-FET sensors 
are based on detection of changes in the electrical field close to the NW surface, this 
might result in low sensitivity of these devices for many protein analytes. We therefore 
decided to study the influence of the net charge of GFP on its detectability in these 
devices. GFP was chosen as model analyte, because binding to its specific antibody 
can be easily verified by fluorescence microscopy upon excitation with a standard 
laser at 488 nm. Furthermore, GFP is only slightly negatively charged at a pH close 
to 7 (isoelectric point of 6.8, as calculated with the software SwissProtParam) and 
therefore serves as a good example for proteins with a low overall charge. By genetic 
engineering, GFP was fused to positively and negatively charged ELP tags of various 
lengths. GFP-ELP fusion proteins were successfully produced in and purified from 
E.coli cells, as described in chapter 4.
Next, the performance of the charge-tagged GFP variants in sensing experiments 
was evaluated using a silicon-nanowire field-effect transistor setup in collaboration 
with Moria Kwiat, Roey Elnathan and Prof. Fernando Patolsky from Tel-Aviv 
University. The basic nanowire sensor chip contains close to 200 devices that can 
be addressed individually for simultaneous detection. The electrical contacts were 
formed by photolithography and metal deposition steps following deposition of the 
Supercharged Tags for Protein Detection in Nanowire Field-Effect Transistors
103
nanowires on the sensor surface. After their fabrication, the transistors were converted 
into sensors for the detection of GFP and its charge-tagged variants by modification 
of the nanowire surface with a monoclonal antibody directed against GFP. Firstly, 
chemical modification of the naturally formed oxide coating was carried out to allow 
coupling of the antibody. In a second step, the antibody was covalently linked to 
the sensor surface, and non-reacted sites were blocked with ethanolamine to avoid 
unspecific binding of analyte molecules. Subsequently, specific binding of GFP to 
the immobilized antibody was studied by fluorescence microscopy. As can be seen 
in Figure 1a, GFP absorbed strongly to the surface that was functionalized with anti-
GFP antibody. Incubation of the non-functionalized surface with GFP resulted in 
only marginal absorption of the protein, indicating that indeed attachment of GFP 
to the surface is mediated by specific binding to the antibody (Figure 1b). Rinsing 
of the antibody-functionalized surface after GFP incubation removed loosely-bound 
protein, resulting in a fluorescence decrease. However, a substantial amount of GFP 
was retained on the surface, confirming specific binding (Figure 1c and d).
Figure 1. Specific binding of GFP to antibody-functionalized sensor surface. Surfaces were (a) 
functionalized with monoclonal antibody against GFP or (b) non-functionalized. (c) Higher magnification 
of the surface shown in (a);  (d) surface as in (c), after rinsing with sensing buffer.  Scale bars: 50 µm (a 
and b) and 5 µm (c and d).
After antibody functionalization and confirmation of specific GFP binding, electrical 
transport characteristics of functional devices were determined. In order to minimize 
device-to-device variation, the electrical responses of the NWs were calibrated.[26] 
Protein solutions of GFP-K9, -K36, -K72, -E9, -E36, and -E72 were delivered through 
a microfluidic channel to the devices and the nanowire conductance was recorded. For 
clarity, GFP-K36 refers to GFP fused to a tag carrying 36 positive charges, whereas 
GFP-E36 refers to GFP fused to a tag carrying 36 negative charges. A schematic 
representation of an antibody-functionalized device is depicted in Figure 2.
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The response of the nanowire devices clearly differed depending on the net 
charge of the delivered protein. Whereas binding of positively charged GFP-ELPs 
resulted in reduced conductance of the nanowire, conductance was increased upon 
binding of negatively charged variants (Figure 3). These findings are in agreement 
with the expectations, as p-type (boron doped) silicon nanowires were used for 
nanodevice fabrication. It is well known that binding of negatively charged molecules 
increases conductance in p-type nanowires, analogously to applying a negative gate 
voltage.[14] Consequently, binding of positively charged molecules will decrease the 
conductance, analogously to applying a positive gate voltage. It is noteworthy that 
these trends were observed for all functional devices in two independent experiments. 
GFP alone did not induce any measureable change in conductance, as expected from 
its low net charge close to neutral pH. However, fusion of GFP to an ELP carrying 
nine positive or negative charges was sufficient to elicit a measureable conductance 
change. Increasing the number of positive charges on the ELP tag to 36 or 72 resulted 
in an increased average response. The highest response was observed for GFP-K36, 
whereas the response to GFP-E36 did not substantially differ from the response to 
GFP-E9 (Figure 3a). It has to be noted, however, that GFP-K36 and GFP-E36 were 
not tested in the first experiment. Furthermore, delivery of GFP-E18 did not elicit 
any response in experiment 1, but induced a decrease in conductance in experiment 
2, whereas GFP-K18 was not detectable in experiment 2 (data nor shown). Upon 
delivery of GFP-ELP variants with 72 and 144 negative charges to the devices in 
Figure 2. Schematic of a silicon-nanowire FET device functionalized with antibody receptors against 
GFP (blue). A GFP variant equipped with a charged tag will bind specifically to the receptor and produce 
a conductance change in the nanowire. Objects are not drawn to scale.
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the first experiment, at a concentration of 100 nM, no change in conductance was 
observed (data not shown). 
Figure 3. Sensing of GFP-ELP variants on NW-FET sensor chips. Graphs show the calibrated 
responses of several devices after delivery of the proteins through a fluid-delivery system. 
Results are from two independent experiments. (a) chip 1, analyte concentration: 100 nM; and 
(b) chip 2, analyte concentration: 20 nM.
A key factor for real-time sensors is their ability to respond and be regenerated 
quickly after operation. Representative time-dependent data for an GFP-ELP variant 
carrying nine positive charges (GFP-K9) show that conductance decreased sharply 
upon injection of the protein solution and stabilized at a lower value a few minutes 
after injection (Figure 4a).  Upon subsequent washing with pure sensing buffer, 
the device responded rapidly within 5 min after buffer exchange, and conductance 
returned to baseline, indicating detachment of the protein from the antibody upon 
dilution. Contrarily, GFP injection did not change the conductance of the devices 
(Figure 4b).
To rule out non-specific binding effects due to electrostatic interaction, sensing 
was performed with the ELP variants K72 and E72, carrying 72 positive and negative 
charges, respectively. Neither variant elicited a response (Figure 4c and d). These 
results clearly showed the selectivity of the system, as the response of the devices is 
strictly dependent upon binding of GFP to the immobilized antibody. 
The results raise the question why GFP with the longest negatively charged 
ELP tag (GFP-E72) did not elicit any response. To check whether binding of GFP 
to the antibody might be impaired for this variant, we conducted an enzyme-linked 
immunosorbent assay (ELISA). In brief, GFP and all GFP fusion variants that were 
tested in the sensing experiments were covalently coupled via the N-terminal amino 
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group to amino-reactive groups on the plate surface. The reaction took place in a 
buffer of pH 7 to favor reaction of the N-terminal amine group over reaction of the 
lysine ε-amine groups. As lysine ε-amine groups are more prevalent in the positively 
charged variants, a higher pH might lead to differences in coupling efficiency. The 
plate was incubated with the mouse monoclonal antibody against GFP, which was 
used in the sensing experiments. Binding of the anti-GFP antibody was detected by an 
enzyme-linked secondary antibody, which catalyzed the reaction of a non-fluorescent 
substrate to a fluorescent product. Fluorescence intensity in GFP-E9 functionalized 
wells was similar to the signal for wells with GFP absorbed. Intensity decreased with 
increasing length of the negatively charged tag (Figure 5a). 
Figure 4. Sensing experiment – real time curves depicting the responses of individual devices to (a) 100 
nM GFP-K9; (b) 100 nM GFP; (c) 20 nM K72; (d) 20 nM E72. GFP, K72, and E72 represent negative 
controls. (a-b) experiment 1; (c-d) experiment 2.
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Intensity for all positively charged GFP-ELP variants was substantially higher 
than for GFP. It can be ruled out that these differences result from unspecific 
electrostatic interactions between the antibody and the positively charged tag, as 
for the negative control K72 only a weak signal was detected, comparable to E72. 
It was therefore necessary to assess whether these differences can be assigned to 
different binding affinities of the antibody depending on the variant, or whether the 
variants only had different reactivities with the plate surface during immobilization. 
Fluorescence microscopy was used to estimate the amounts of protein adsorbed to 
the plate, taking advantage of the inherent fluorescence of GFP. Despite the fact 
that the same concentration was used for all GFP variants during incubation, the 
mean fluorescence was strongly reduced for negatively charged variants and strongly 
increased for the shorter positively charged variants (Figure 5b). These findings 
indicate that adsorption is highly dependent on the charge nature and the amount 
of charges on the ELP tag. We therefore conclude that the performed ELISA test is 
not suitable to answer the question why GFP-E72 did not elicit any response in the 
sensing experiments. 
Figure 5. Relative binding affinities of anti-GFP antibody to GFP-ELP variants. (a) ELISA 
with primary antibody against GFP and enzyme-linked secondary antibody for detection 
via formation of a fluorescent product. GFP-ELP concentration was 0.2 µM for all variants 
during incubation on the plate. Relative fluorescence values are averages of two experiments 
with each experiment performed in hexaplicate. (b) Mean fluorescence of GFP-ELP variants 
absorbed to ELISA plate, determined by fluorescence microscopy and background-subtracted. 
Fluorescence micrographs were taken after incubation with the protein solution and washing. 
Dashed line: mean fluorescence of GFP, after incubation of 0.2 µM GFP solution. Protein 
concentration was 0.2 µM during incubation on the plate, if not otherwise stated. 
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A sandwich ELISA was tried and proved to be unsuitable as well. In this second 
ELISA setup the anti-GFP antibody was coupled to the plate, and binding of GFP 
was assessed by detection with a second antibody directed against the C-terminal His 
tag. This assay resembled more closely the situation in the sensing device, where the 
antibody was immobilized on the plate and GFP was delivered in the mobile phase. 
However, the background signal was found to be in the range of the signal, due to 
unspecific absorption of GFP to the plate (data not shown).
CONCLUSIONS AND OUTLOOK
In this work, we successfully demonstrated that proteins targets equipped with a 
supercharged ELP tag are suitable for detection in SiNW-FETs, while the pristine 
protein does not elicit any signal at all. Already a moderate change in net charge 
due to fusion with a short charged ELP tag greatly enhances the detectability of a 
protein target in a nanowire field-effect transistor setup. Initial experiments with 
ELP tags carrying different numbers of charges indicate that longer tags induce a 
larger change in nanowire conductivity. However, a very high number of charges can 
suppress the signal, as was seen for the longest negatively charged tags E72 and E144. 
Further experiments are needed to determine the optimal length of supercharged 
tags in SiNW-FET devices. A detailed statement about the optimum length to elicit 
maximum response cannot be given at this point. Furthermore, it remains to clarify 
the mechanisms by which the charged ELP tag influences the device response. 
We tried to elucidate whether the ELP tag interferes with the binding of the GFP-
fusion protein by the antibody, and, if yes, whether this interference is dependent 
on the length of the tag. However, all ELISA setups that were employed proved 
to be unsuitable to answer this question. Instead, this question might be addressed 
by confocal fluorescence imaging. As shown in this work, binding of GFP by the 
antibody immobilized on the sensor surface can be directly visualized. Binding 
affinities of the antibody to the different GFP-ELP variants need to be quantified by 
determining fluorescence intensity on the modified sensor surface after incubation 
with the fusion proteins. 
Taken together, further experiments are needed to determine the optimum tag length 
and charge and to elucidate the mechanisms by which the ELP tag influences GFP 
detection by the device. Nevertheless, the results presented here are very promising 
and provide a successful proof-of-concept of the application of supercharged fusion 
proteins in NW-FET devices.




All chemicals were used as purchased without any further purification. Fabrication 
and characterization of the analyte proteins was described in chapter 4. Mouse 
monoclonal [6AT316] antibody to GFP and rabbit anti-Mouse IgG H&L (HRP) 
secondary antibody were purchased from Abcam (Cambridge, UK). Phosphate buffer 
solution (PBS) tablets were obtained from Sigma-Aldrich (Steinheim, Germany). 
Tween20 was purchased from Bio-Rad Laboratories (Hercules, CA). Bovine serum 
albumin was obtained from Carl Roth GmbH (Karlsruhe, Germany). Solvents were 
purchased from Biolab Ltd., Israel. Silicon wafers with 600 nm thermal oxide, SSP 
prime grade, were obtained from Silicon Quest International. Glutaraldehyde, sodium 
cyanoborohydride and ethanolamine were purchased from Sigma-Aldrich (Israel). 
All other chemicals were purchased from KGaA (Darmstadt, Germany). Water with 
a resistivity > 18 MΩ was used for all experiments.
SiNW synthesis, device fabrication, and surface functionalization 
Si-NW synthesis and device array fabrication
Silicon nanowires were synthesized by chemical vapor deposition as described 
previously.[27] Briefly, 20-nm-diameter gold nanoparticles served as catalyst sites for 
the growth of SiNWs on Si (100) growth substrates, covered with poly-lysine to 
promote adhesion of the gold nanoparticles to the substrate. For growth of p-doped 
SiNWs, the Si wafer was placed in a horizontal tube furnace, with silane (SiH4) and 
diborane (B2H6) as reactants in a ratio of 1:4000 in the gas phase. SiNW FET devices 
and the polydimethylsiloxane (PDMS) fluid delivery system were fabricated as 
described previously.[19] In short, source and drain electrodes were deposited on the 
Si-NWs using a multilayer photoresist structure. After exposure and development of 
the electrode pattern, the contacts were metallized by e-beam and thermal evaporation 
of Ti/Pd/Ti (5/60/8) nm. Contacts were passivated with an insulating layer (100 nm) 
of Si3N4 deposited by plasma-enhanced chemical vapor deposition. The fluid delivery 
system was fabricated from flexible PDMS elastomer, using a master-SU8 template. 
PDMS was mixed 10:1 with base as a curing agent, cured overnight at 60 °C and cut 
into rectangular pieces of 10 x 10 x 5 cm. The PDMS channel was clamped to the 
wafer in respect to the NW-devices.
Surface Functionalization with anti-GFP antibody
Prior to chemical modification, the sensor device was cleaned by oxygen plasma 
treatment for effective chemical modification of the hydroxyl-terminated surface. 
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Substrates were then modified with 1% (v/v) 3-aminopropyltriethoxysilane (APTES) 
in ethanol/H2O (95%/5%) for 1 h at room temperature, followed by a thorough rinse 
with isopropyl alcohol and baking on a hot plate at 115 °C for 3 hr. In order to 
provide aldehyde terminal groups, the APTES-modified surface was modified with 
glutaraldehyde by immersing the sensor chip in phosphate buffer solution (PBS) 
containing 2.5% glutaraldehyde with 4mM sodium cyanoborohydride (NaBH3CN) 
at pH 8 for 2 h, followed by a through wash with water and isopropyl alcohol. A 
solution of monoclonal anti-GFP antibody (100 μg/ml (in 10 mM phosphate buffer, 
pH 8.4, containing 4 mM NaBH3CN was delivered into the PDMS channel for 4 h 
at a flow rate of 4 µl/min at room temperature, followed by a washing step with 10 
mM phosphate buffer, pH 8.4. Unreacted terminal aldehyde groups were passivated 
by flushing the PDMS chamber for 1-2 h with 100 mM ethanolamine in 10 mM 
phosphate buffer, pH 8.4, containing 4 mM NaBH3CN, followed by washing with 10 
mM phosphate buffer, pH 8.4. 
Analyte Binding Control with Confocal Fluorescence Imaging
A rectangular piece of cured PDMS with 2 to 3 mm holes was sealed to a Si/SiO2 
wafer functionalized with anti-GFP antibody as described above.  A wafer that was 
not functionalized with the antibody served as a control. GFP at a concentration of 
100 µg/ml in sensing buffer (PBS, 1:1000 in MilliQ) was added to the holes and 
incubated for 2 h. The GFP solution was removed and the chip was rinsed with 
sensing buffer for 1 min. Fluorescence micrographs of the surfaces were taken before 
and after rinsing of the wafers. Micrographs were recorded on a Leica SP5 confocal 
microscope equipped with an X63 1.4 NA Plan-Apo oil immersion objective. Images 
were acquired upon excitation at 488 nm and by recording emission between 500 and 
550 nm using LASAF software. 
Analyte Preparation, Sensing and Electrical Characterization
Protein sample preparation
Lyophilized proteins were dissolved in 50 mM NaCl solution to a concentration of 
1 mg/mL, frozen in liquid nitrogen in aliquots and stored at -18 °C until further use. 
For sensing experiments, an aliquot (2 x 10-12 mol) was thawed on ice, filled up to 
100 µL with sensing buffer to reach a final concentration of 200 nM, and dialyzed 
against sensing buffer overnight. The sample was then diluted with sensing buffer to 
the desired protein concentration (200 pM to 200 nM).
Sensing experiments were performed as described previously.[19] Briefly, the 
conductance of the Si-NW FET was measured by application of an AC bias (70 kHz, 
100 mV) by means of a lock-in amplifier (Stanford Research System model SR830 
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DSP). The drain current was amplified with a variable-gain amplifier (model 99539 
Amplifier System) and filtered by the lock-in amplifier with a time-constant setting 
of 300 ms. Data were recorded using a multichannel I/O adaptor panel (BNC-2090, 
National Instrument). Prior to real time electrical detection, the sensor chip was 
washed with sensing buffer.  Protein analytes were delivered to the SiNW FET sensor 
chip by the microfluidic system using a syringe pump (Solomite Mitos Syringe Pump 
XS) at a flow rate of 5 µL/min, and conductance of the SiNW devices was monitored 
over time. All studies were carried out at room temperature. In order to decrease 
device-to-device variation, the device responses were calibrated by dividing the 
absolute response, i.e. the absolute change in current ΔI, by the NW gate dependence 
(dIds/dVg) for each device.
[26] 
Enzyme-linked immunosorbent assay (ELISA)
Freeze-dried proteins were dissolved in coupling buffer (0.1 M sodium phosphate 
buffer, pH 7.0). Insoluble protein was removed by centrifugation (16,000 x g, 5 min, 
6 °C), and protein concentration in the supernatant was determined by measuring 
absorbance at 280 nm. Protein solutions were diluted in coupling buffer to a 
concentration of 0.2 µM. 100 µl of protein solution was added to each well of a 
Nunc Immobilizer Amino F96 black plate. During all incubation steps the plate was 
wrapped in cling film to prevent evaporation of liquid. For coupling, the plate was 
incubated at 7°C o/n. After incubation, the liquid was removed. To block unreacted 
sites on the plate, 300 µl of blocking buffer (2% bovine serum albumin in 0.1 M 
sodium phosphate buffer, pH 8.0) were added to each well. The plate was incubated 
for 2 h at 7°C. Each well was washed 4 times with sensing buffer. Mouse monoclonal 
[6AT316] immunoglobulin G (IgG) antibody to GFP was diluted 1:1,000 in sensing 
buffer. 100 µl of antibody solution was added to each well and incubated for 30 
min at room temperature (RT) whilst shaking at 800 rpm. Antibody solution was 
removed and wells were washed once with 300 µl sensing buffer and 5 times with 
300 µl wash buffer (0.1 % bovine serum albumin and 0.1 % Tween20 in PBS) per 
well. HRP conjugated rabbit polyclonal antibody to mouse IgG was diluted 1:1,000 
in wash buffer. 100 µl were added to each well and incubated for 30 min at RT 
whilst shaking at 800 rpm. All wells were washed 5 times with wash buffer and once 
with sensing buffer. Antibody detection was performed with the QuantaBlu detection 
kit according to the manufacturer’s protocol. 100 µl of the freshly mixed substrate/
peroxide solution was added to each well. Fluorescence at 420 nm after excitation at 
325 nm was measured on a SpectraMax M2 (Molecular Devices, Sunnyvale, CA) for 
4 h in intervals of 2 min. 
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Fluorescence microscopy of ELISA plates
Concentrated protein solutions were prepared as described for ELISA.  A dilution 
series (0.05 to 0.8 µM) of GFP in coupling buffer was prepared. GFP-ELP variants 
were diluted in coupling buffer to a concentration of 0.2 µM. 100 µl of protein 
solution were added to each well of a Nunc Immobilizer Amino F96 clear plate. 
During all incubation steps the plate was wrapped in cling film to prevent evaporation 
of liquid. For coupling, the plate was incubated at 7°C o/n. After incubation, the 
liquid was removed. To block unreacted sites on the plate, 300 µl of blocking buffer 
(2% bovine serum albumin (BSA) in 0.1 M Na-P, pH 8.0) were added to each well. 
The plate was incubated for 2 h at 7°C. Blocking solution was exchanged for 300 µl 
of PBS per well. 
Fluorescence images were recorded in epifluorescence mode using an EM-CCD 
camera (ImagEM / Hamamatsu, Japan) connected to an inverted microscope (IX71 
/ Olympus, Germany). GFP was excited with a continuous-wave solid-state laser at 
488 nm, which was coupled into the microscope and focused onto the sample via an 
air objective (LUCPlanFLN 40x/0.6 / Olympus, Germany). The power at the focal 
point amounted to 570 µW. The emitted fluorescence was collected and separated 
from the excitation wavelength using a single-band dichroic filter (T495LP, Chroma, 
VT, USA) and a bandpass filter (HQ550/100m, Chroma, VT, USA). During each 
measurement, a sequence of 1000 frames was recorded with an exposure time of 
100 ms. These images were averaged afterwards and then evaluated. Since the images 
just showed a slight uniform gradient in fluorescence due to the beam-profile (but no 
additional structures) the same inset in all averaged images was analyzed statistically. 
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Electrostatic interactions rely on the effect that positive and negative charges 
attract each other, whereas two positive or two negative charges repel each other. 
Electrostatic effects play an important role in many processes that take place in 
living organisms, and many structures and molecules inside the cell bear charges. 
The carrier of genetic information, deoxyribonucleic acid (DNA) is negatively 
charged. Proteins, on the other hand, can be positively or negatively charged. As they 
carry out many functions in living organisms, a great variety of different proteins is 
needed. This variety is attained by the fact that the 20 natural amino acids (i.e. the 
building blocks of proteins) can be used in virtually any combination. Among the 
natural amino acids two positively and two negatively charged ones occur under 
physiological conditions. Structure and function of a protein are defined by the amino 
acid sequence, which is encoded in the genetic information. Changing the genetic 
information - a process called genetic manipulation - therefore actually means to 
modify the “construction plan” of a protein. The genetic information is delivered into 
a host organism (a bacterial cell, for example), which then produces the modified 
protein. In this way, also the charge of a protein can be altered: When negatively 
charged amino acids are exchanged by positively charged ones, the modified protein 
is highly positively charged, and vice versa. Two such proteins repel each other, but 
are attracted to everything that is negatively charged. Chapter 1 describes how such 
“supercharged” proteins are used for a wide variety of applications in medicine, 
biological research and material science. 
Many proteins form compact, well-defined structures in solution. The proteins 
described in this thesis, however, exhibit a flexible backbone. They were designed 
in such a way that they have positive or negative charges at equal distances along 
the amino acid chain and are able to interact with oppositely charged molecules and 
objects (chapter 2). As they do not fold into three-dimensional structures in solution, 
they are called supercharged, unfolded proteins (SUPs). We decided to investigate 
whether positively charged (cationic) SUPs can bind to mucins, highly negatively 
charged proteins with sugar chains attached along the protein chain (chapter 3). 
Mucins are a component of saliva and are responsible for lubrication in the mouth: 
They form a viscous film on teeth, tongue and mucosa to reduce friction between sliding 
surfaces. Saliva needs to be constantly produced, because the salivary conditioning 
film can be damaged due to mechanical stress (during speaking and chewing) or 
dilution (during eating and drinking). Patients who suffer from dry-mouth disease 
do not produce enough saliva and consequently experience pain when they speak or 
eat. These patients are prescribed special toothpastes or mouth-rinses, but their effect 
does not last very long, and most patients still complain about a perception of dryness 
in the mouth after the application. Together with Dr. Prashant Sharma and Deepak 
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Veeregowda at the University Medical Center Groningen, we investigated whether 
treatment with cationic SUPs could stabilize salivary conditioning films in these 
patients. We therefore mimicked the real situation in which a patient would rinse his/
her mouth with the protein solution. Salivary conditioning films were created on a 
plain surface, which were first rinsed with the protein solution and then with saliva. 
We observed that the films indeed became more resistant to mechanical stress after 
treatment with a long variant of cationic SUP. Moreover, the lubrication properties 
of the treated films were considerably improved compared to untreated films. These 
results raise the hope that treatment with cationic SUPs will increase the comfort of 
patients with dry-mouth disease in the future.    
Next, we examined whether it is possible to build structures from SUPs on the 
micro-and nanometer scale (i.e. a thousandth to a millionth part of a millimeter in 
size). Such structures can find applications as carrier systems for drugs and other 
bioactive compounds that are injected into the blood stream. The use of a carrier 
system has at least two advantages: Firstly, the active compound is shielded from 
agents that can inactivate it before it reaches its target. Secondly, the carrier system 
can be directed to the target site and trigger the uptake of its load by those cells that 
are to be treated, but not by other cells in the body. In this way, side effects can be 
substantially reduced. In collaboration with Prof. Parak’s group at the University 
of Marburg, Germany, we fabricated micrometer-sized, hollow capsules from SUPs 
(chapter 2). We built the capsule wall of consecutive layers of anionic and cationic 
SUPs on a spherical core; thereby the electrostatic attraction between oppositely 
charged SUPs served as a kind of “glue” between the ten or more layers. After the 
assembly of the wall, the core was destroyed, and the hollow shell proved to be 
stable, as it preserved its round shape. It had been shown before that proteins can be 
loaded into the cavity of electrostatically assembled capsules and that these capsules 
are taken up by cells in culture (i.e. cells that are grown in a culture medium in the 
laboratory). We wanted to see whether proteins can also be loaded into the capsule 
wall (chapter 4). To this end a cationic SUP variant was fused to green fluorescent 
protein (GFP). As GFP is fluorescent, it lights up as green spots under a fluorescence 
microscope when excited with blue light. This enables us to see where GFP is located 
in a sample. The SUP served as an electrostatic “anchor” to incorporate GFP into the 
capsule wall. The capsules were fabricated as described in chapter 2, but this time 
one layer was composed of the GFP fusion protein. The capsules were indeed taken 
up by cells in culture, and we were able to follow their fate inside the cells under a 
fluorescence microscope. These results serve as a proof-of-principle that the shell of 
multilayer capsules can be functionalized by electrostatic anchoring using a SUP tag 
fused to a charge neutral or moderately charged protein. 
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Finally, we investigated how GFP-SUP fusion proteins perform in supersensitive 
detection (chapter 5). Supersensitive detectors are able to sense compounds even 
at very low concentrations. Therefore they are promising tools for a broad range 
of applications like the fast diagnosis of heart attacks or dangerous infections and 
the detection of explosives or pesticides, just to name a few. Together with Prof. 
Patolski’s group at Tel-Aviv University, Israel, we developed a detector for GFP based 
on a nanowire field-effect transistor (NW-FET). This kind of detector senses changes 
in the charge distribution around a semiconducting wire. The field is changed when 
a charged object comes into close proximity with the wire surface. Due to the fact 
that the wires have a large surface to volume ratio, even small particles (like proteins, 
for example) cause a measureable field change. We created series of positively and 
negatively charged GFP-SUP fusion proteins with various lengths of the SUP part 
and measured the effect of the charged tag on the detectability of GFP. As GFP is 
only moderately charged, it was not detectable by our system. However, already 
the smallest tags with nine charges were sufficient to sense binding of GFP to the 
nanowires. Furthermore, the results indicated that positively charged tags perform 
slightly better than negatively charged ones. Experiments like these will help to better 
understand the factors that influence measurements in NW-FETs and to improve the 











Elektrostatische interacties zijn gebaseerd op het effect dat positieve en negatieve 
ladingen elkaar aantrekken, terwijl twee positieve of twee negatieve ladingen elkaar 
afstoten. Elektrostatische effecten spelen een belangrijke rol in veel processen die 
plaatsvinden in levende organismen, en veel onderdelen en moleculen in de cel 
hebben ladingen. De drager van genetische informatie, desoxyribonucleïnezuur 
(DNA), is negatief geladen. Eiwitten aan de andere kant kunnen positief of negatief 
geladen zijn. Omdat ze veel functies in levende organismen vervullen, is een grote 
variëteit aan verschillende eiwitten nodig. Deze variëteit wordt verkregen door het 
feit dat de 20 natuurlijke aminozuren (de bouwstenen van eiwitten) gebruikt kunnen 
worden in vrijwel elke combinatie. Onder de natuurlijke aminozuren komen twee 
positief en twee negatief geladen voor onder fysiologische condities. De structuur en 
functie van een eiwit worden bepaald door de aminozuur volgorde, die is vastgelegd 
in de genetische code. Verandering van de genetische code – een proces genaamd 
genetische manipulatie – houdt dus eigenlijk een verandering van het “bouwplan” 
van een eiwit in. De genetische informatie wordt bezorgd in een host organisme (een 
bacterie bijvoorbeeld), die vervolgens het gemodificeerde eiwit produceert. Via deze 
weg kan ook de lading van een eiwit worden veranderd: wanneer negatief geladen 
worden vervangen door positief geladen eiwitten, dan is het gemodificeerde eiwit 
hoog positief geladen, en vice versa. Twee van zulke eiwitten stoten elkaar af, maar 
worden aangetrokken door alles wat negatief geladen is. Hoofdstuk 1 beschrijft hoe 
zulke “supergeladen” eiwitten worden gebruikt in een verscheidenheid aan applicaties 
in medicijnen, biologisch onderzoek en materiaalwetenschapen.
Veel eiwitten vormen compacte, goed gedefinieerde structuren in oplossingen. 
Echter, de eiwitten beschreven in dit proefschrift vertonen een flexibele structuur. 
Ze zijn zo ontworpen dat ze positieve of negatieve ladingen op gelijke afstand 
hebben over de gehele lengte van aminozuren en hebben interactie met moleculen 
en objecten van tegengestelde lading (hoofdstuk 2). Omdat ze in oplossing niet 
in een driedimensionale structuur vouwen, worden ze “supercharged, unfolded 
proteins” (hoogeladen, ongevouwen eiwitten; SUPs) genoemd. We hebben besloten 
te onderzoeken of positief geladen (kationische) SUPs kunnen binden aan mucines, 
hoog negatief geladen eiwitten met suiker ketens aan de eiwit keten (hoofdstuk 3). 
Mucines zijn een onderdeel van het speeksel en zijn verantwoordelijk voor de smering 
van de mond: ze vormen een viskeuze film op de tanden, tong en het slijmvlies om 
de frictie tussen schuivende oppervlakken te verminderen. Speeksel moet constant 
geproduceerd worden omdat de film beschadigd kan worden door mechanische stress 
(tijdens het praten of kauwen) of verdunning (tijdens het eten en drinken). Patiënten 
die aan de droge mond ziekten lijden produceren niet genoeg speeksel en ervaren pijn 
tijdens het praten en eten. Deze patiënten krijgen speciale tandpasta of mondwater 
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voorgeschreven, maar hiervan duurt het effect niet lang en de meeste patiënten klagen 
nog steeds over droogte in de mond na het nemen hiervan. Samen met Dr. Prashant 
Sharma en Deepak Veeregowda van het Universitair Medisch Centrum Groningen 
hebben we onderzocht of behandeling met kationische SUPs de speekselfilm van 
deze patiënten kan stabiliseren. Daarom hebben we de werkelijke situatie nagebootst 
waarin een patiënt zijn/haar mond spoelt met de eiwitoplossing. Speekselfilms zijn 
gemaakt op een recht oppervlak en vervolgens eerst met de eiwit oplossing gewassen 
en daarna met speeksel. Er is gebleken dat de films inderdaad beter resistent waren 
tegen mechanische stress na behandeling met de lange variant van kationische SUPs. 
Bovendien bleek de smering van de behandelde films behoorlijk verbeterd te zijn in 
vergelijking met onbehandelde films. Deze resultaten bieden de hoop dat behandeling 
waarbij gebruik wordt gemaakt van kationische SUPs het leven voor patiënten met 
een droge mond aandoening in de toekomst dragelijker zal maken.
Vervolgens hebben we onderzocht of het mogelijk is om structuren te maken van 
SUPs op micro- en nanometer schaal (een duizendste en een miljoenste meter omvang). 
Zulke structuren kunnen gebruikt worden als dragersystemen voor medicijnen en 
andere bioactieve verbindingen die worden geïnjecteerd in de bloedbaan. Het gebruik 
van dragersystemen heeft tenminste twee voordelen: Ten eerste is het actieve middel 
beschermd tegen vernietiging voordat het doel wordt bereikt. Ten tweede kan het 
systeem gestuurd worden naar de doellocatie en de opname door de beoogde cellen 
versterken terwijl andere lichaamscellen buiten schot blijven. Hierdoor kunnen 
bijwerkingen aanzienlijk worden verminderd. In samenwerking met Prof. Parak’s 
groep aan de universiteit van Marburg, Duitsland, hebben we micrometer grote holle 
capsules gemaakt van SUPs (hoofdstuk 2). We hebben de capsule wand gebouwd van 
opeenvolgende lagen van anionische en kationische SUPs op een ronde kern; waarbij 
de elektrostatische interactie tussen de tegengesteld geladen SUPs als een soort lijm 
dient tussen de tien of meer lagen. Na vorming van de wand is de kern verwijderd 
en bleken de holle capsules hun ronde vorm te behouden. Er is eerder getoond dat 
eiwitten geladen kunnen worden in de ruimte van elektrostatisch gevormde capsules 
en dat deze capsules opgenomen worden door cultuur cellen (dit zijn cellen die 
gegroeid worden in cultuur medium in een laboratorium). Wij hebben onderzocht 
of dergelijke eiwitten ook in de wand kunnen worden ingebouwd (hoofdstuk 4). 
Zodoende is de kationische SUP variant gefuseerd met het “green fluorescent protein” 
(GFP). Omdat GFP fluoriserend is, is het zichtbaar als een groene plek onder een 
fluorescentie microscoop wanneer er belicht wordt met blauw licht. Dit maakt het 
mogelijk te zien waar de GFP gesitueerd is in het monster. De SUP dient als een 
elektrostatisch anker om de GFP te incorporeren in de capsule wand. De capsules zijn 
gemaakt zoals beschreven in hoofdstuk 2, maar deze keer is een laag gemaakt van 
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het GFP fusie eiwit. Deze capsules worden inderdaad opgenomen door cultuur cellen 
en we waren in staat om hun bestemming in de cel te volgen met behulp van een 
fluorescentie microscoop. Deze resultaten dienen als proof-of-concept voor het feit 
dat een meerderelaags capsule gefunctionaliseerd kan worden door het elektrostatisch 
verankeren met een SUP gefuseerd met een neutraal of licht geladen eiwit.
Tenslotte hebben we onderzocht hoe GFP-SUP fusie eiwitten presteren in 
supergevoelige detectie (hoofdstuk 5). Supergevoelige detectoren zijn in staat om 
verbindingen te herkennen op zeer lage concentraties. Daarom zijn ze veelbelovend 
gereedschap voor een brede range aan toepassingen zoals snelle diagnose van een 
hartstilstand of gevaarlijke infecties en de opsporing van explosieven en pesticiden. 
Samen met Prof. Patolski’s groep aan de universiteit van Tel-Aviv, Israel, is een 
detector voor GFP ontwikkeld die gebruik maakt van “nanowire field-effect 
transistors” (NW-FETs). Dergelijke detectoren zijn gevoelig voor een verandering 
in de ladingsverdeling rondom een halfgeleidende draad. Het veld wordt veranderd 
wanneer een geladen object in de nabijheid komt van het oppervlak. Doordat de 
draden een grote oppervlak-volume ratio hebben kunnen zelfs kleine deeltjes (zoals 
eiwitten bijvoorbeeld) een meetbare verandering in het veld veroorzaken. Wij hebben 
een serie van verschillende positief en negatief geladen GFP-SUP fusie eiwitten 
gemaakt, met verschillende lengtes van het SUP gedeelte, en het effect gemeten van 
het geladen label aan GFP. Omdat GFP licht geladen is, is het niet detecteerbaar met 
ons systeem. Echter, het kleinste label met negen ladingen was genoeg om binding van 
GFP aan de nanometer dikke draad te detecteren. Bovendien laten de resultaten zien 
dat positief geladen labels iets beter werken dan negatief geladen labels. Dergelijke 
experimenten helpen een beter inzicht te krijgen in de factoren die een rol spelen in 
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